Question_index,prompt,Asking_therapy,Given_biomarker,Question_category,Is_there_an_approval,Groundtruth_answers,Groundtruth_therapies,matching_cnt,missing_cnt,hallucinating_cnt,no_output_cnt,RAGLLM_drug_output_0,RAGLLM_drug_output_1,RAGLLM_drug_output_2,RAGLLM_drug_output_3,RAGLLM_drug_output_4,RAGLLM_full_output_0,RAGLLM_full_output_1,RAGLLM_full_output_2,RAGLLM_full_output_3,RAGLLM_full_output_4,RAGLLM_input_prompt_0,RAGLLM_input_prompt_1,RAGLLM_input_prompt_2,RAGLLM_input_prompt_3,RAGLLM_input_prompt_4
q0,What is the first-line treatment of metastatic urothelial carcinoma with FGFR3 S249C mutation? ,True,True,"given disease and biomarker, return drugs",True,erdafitinib,[{'erdafitinib'}],1,0,0,0,{frozenset({'erdafitinib'})},{frozenset({'erdafitinib'})},{frozenset({'erdafitinib'})},{frozenset({'erdafitinib'})},{frozenset({'erdafitinib'})},"{
    ""Status"": ""success"",
    ""Treatment 1"": {
        ""Disease Name"": ""Urothelial Carcinoma"",
        ""Disease Phase or Condition"": ""Locally advanced or metastatic"",
        ""Drug Name"": ""Erdafitinib"",
        ""Prior Treatment or Resistance Status"": ""Progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy"",
        ""Genomic Features"": ""FGFR3 (c.746C>G or p.S249C)"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf""
    }
}","{
    ""Status"": ""success"",
    ""Treatment 1"": {
        ""Disease Name"": ""Urothelial Carcinoma"",
        ""Disease Phase or Condition"": ""Locally advanced or metastatic"",
        ""Drug Name"": ""Erdafitinib"",
        ""Prior Treatment or Resistance Status"": ""Progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy"",
        ""Genomic Features"": ""FGFR3 (c.746C>G or p.S249C)"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf""
    }
}","{
    ""Status"": ""success"",
    ""Treatment 1"": {
        ""Disease Name"": ""Urothelial Carcinoma"",
        ""Disease Phase or Condition"": ""Locally advanced or metastatic"",
        ""Drug Name"": ""Erdafitinib"",
        ""Prior Treatment or Resistance Status"": ""Progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy"",
        ""Genomic Features"": ""FGFR3 (c.746C>G or p.S249C)"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf""
    }
}","{
    ""Status"": ""success"",
    ""Treatment 1"": {
        ""Disease Name"": ""Urothelial Carcinoma"",
        ""Disease Phase or Condition"": ""Locally advanced or metastatic"",
        ""Drug Name"": ""Erdafitinib"",
        ""Prior Treatment or Resistance Status"": ""Progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy"",
        ""Genomic Features"": ""FGFR3 (c.746C>G or p.S249C)"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf""
    }
}","{
    ""Status"": ""success"",
    ""Treatment 1"": {
        ""Disease Name"": ""Urothelial Carcinoma"",
        ""Disease Phase or Condition"": ""Locally advanced or metastatic"",
        ""Drug Name"": ""Erdafitinib"",
        ""Prior Treatment or Resistance Status"": ""Progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy"",
        ""Genomic Features"": ""FGFR3 (c.746C>G or p.S249C)"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf""
    }
}","
    Context information is below.
    ---------------------
    ['If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', ""If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Cisplatin + Osimertinib + Pemetrexed. The U.S. Food and Drug Administration (FDA) has granted approval to osimertinib in combination with platinum-based chemotherapy and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 p.L858R variants, as detected by an FDA-approved test. The efficacy of this indication was demonstrated in a randomized, multicenter, open-label trial (FLAURA2 [NCT04035486]), where patients enrolled in the study arm received osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin while patients of the control arm received osimertinib monotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf. Revised February 2024. Accessed March 4, 2024.)."", ""If a non-small cell lung cancer patient has a somatic variant in gene EGFR (exon 19 deletion), one recommended treatment would be Cisplatin + Osimertinib + Pemetrexed. The U.S. Food and Drug Administration (FDA) has granted approval to osimertinib in combination with platinum-based chemotherapy and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 p.L858R variants, as detected by an FDA-approved test. The efficacy of this indication was demonstrated in a randomized, multicenter, open-label trial (FLAURA2 [NCT04035486]), where patients enrolled in the study arm received osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin while patients of the control arm received osimertinib monotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf. Revised February 2024. Accessed March 4, 2024.)."", 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (nonsense), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: What is the first-line treatment of metastatic urothelial carcinoma with FGFR3 S249C mutation? 
     
    ","
    Context information is below.
    ---------------------
    ['If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', ""If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Cisplatin + Osimertinib + Pemetrexed. The U.S. Food and Drug Administration (FDA) has granted approval to osimertinib in combination with platinum-based chemotherapy and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 p.L858R variants, as detected by an FDA-approved test. The efficacy of this indication was demonstrated in a randomized, multicenter, open-label trial (FLAURA2 [NCT04035486]), where patients enrolled in the study arm received osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin while patients of the control arm received osimertinib monotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf. Revised February 2024. Accessed March 4, 2024.)."", ""If a non-small cell lung cancer patient has a somatic variant in gene EGFR (exon 19 deletion), one recommended treatment would be Cisplatin + Osimertinib + Pemetrexed. The U.S. Food and Drug Administration (FDA) has granted approval to osimertinib in combination with platinum-based chemotherapy and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 p.L858R variants, as detected by an FDA-approved test. The efficacy of this indication was demonstrated in a randomized, multicenter, open-label trial (FLAURA2 [NCT04035486]), where patients enrolled in the study arm received osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin while patients of the control arm received osimertinib monotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf. Revised February 2024. Accessed March 4, 2024.)."", 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (nonsense), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: What is the first-line treatment of metastatic urothelial carcinoma with FGFR3 S249C mutation? 
     
    ","
    Context information is below.
    ---------------------
    ['If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', ""If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Cisplatin + Osimertinib + Pemetrexed. The U.S. Food and Drug Administration (FDA) has granted approval to osimertinib in combination with platinum-based chemotherapy and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 p.L858R variants, as detected by an FDA-approved test. The efficacy of this indication was demonstrated in a randomized, multicenter, open-label trial (FLAURA2 [NCT04035486]), where patients enrolled in the study arm received osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin while patients of the control arm received osimertinib monotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf. Revised February 2024. Accessed March 4, 2024.)."", ""If a non-small cell lung cancer patient has a somatic variant in gene EGFR (exon 19 deletion), one recommended treatment would be Cisplatin + Osimertinib + Pemetrexed. The U.S. Food and Drug Administration (FDA) has granted approval to osimertinib in combination with platinum-based chemotherapy and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 p.L858R variants, as detected by an FDA-approved test. The efficacy of this indication was demonstrated in a randomized, multicenter, open-label trial (FLAURA2 [NCT04035486]), where patients enrolled in the study arm received osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin while patients of the control arm received osimertinib monotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf. Revised February 2024. Accessed March 4, 2024.)."", 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (nonsense), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: What is the first-line treatment of metastatic urothelial carcinoma with FGFR3 S249C mutation? 
     
    ","
    Context information is below.
    ---------------------
    ['If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', ""If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Cisplatin + Osimertinib + Pemetrexed. The U.S. Food and Drug Administration (FDA) has granted approval to osimertinib in combination with platinum-based chemotherapy and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 p.L858R variants, as detected by an FDA-approved test. The efficacy of this indication was demonstrated in a randomized, multicenter, open-label trial (FLAURA2 [NCT04035486]), where patients enrolled in the study arm received osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin while patients of the control arm received osimertinib monotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf. Revised February 2024. Accessed March 4, 2024.)."", ""If a non-small cell lung cancer patient has a somatic variant in gene EGFR (exon 19 deletion), one recommended treatment would be Cisplatin + Osimertinib + Pemetrexed. The U.S. Food and Drug Administration (FDA) has granted approval to osimertinib in combination with platinum-based chemotherapy and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 p.L858R variants, as detected by an FDA-approved test. The efficacy of this indication was demonstrated in a randomized, multicenter, open-label trial (FLAURA2 [NCT04035486]), where patients enrolled in the study arm received osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin while patients of the control arm received osimertinib monotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf. Revised February 2024. Accessed March 4, 2024.)."", 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (nonsense), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: What is the first-line treatment of metastatic urothelial carcinoma with FGFR3 S249C mutation? 
     
    ","
    Context information is below.
    ---------------------
    ['If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', ""If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Cisplatin + Osimertinib + Pemetrexed. The U.S. Food and Drug Administration (FDA) has granted approval to osimertinib in combination with platinum-based chemotherapy and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 p.L858R variants, as detected by an FDA-approved test. The efficacy of this indication was demonstrated in a randomized, multicenter, open-label trial (FLAURA2 [NCT04035486]), where patients enrolled in the study arm received osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin while patients of the control arm received osimertinib monotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf. Revised February 2024. Accessed March 4, 2024.)."", ""If a non-small cell lung cancer patient has a somatic variant in gene EGFR (exon 19 deletion), one recommended treatment would be Cisplatin + Osimertinib + Pemetrexed. The U.S. Food and Drug Administration (FDA) has granted approval to osimertinib in combination with platinum-based chemotherapy and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 p.L858R variants, as detected by an FDA-approved test. The efficacy of this indication was demonstrated in a randomized, multicenter, open-label trial (FLAURA2 [NCT04035486]), where patients enrolled in the study arm received osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin while patients of the control arm received osimertinib monotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf. Revised February 2024. Accessed March 4, 2024.)."", 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (nonsense), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: What is the first-line treatment of metastatic urothelial carcinoma with FGFR3 S249C mutation? 
     
    "
q1,Are PARP inhibitors used for patients with leiomyosarcoma who have mutations in DNA damage repair genes?,True,True,"given disease and biomarker, return drugs",False,PARP inhibitors are not yet approved for the treatment of patients with leimyosarcoma with mutations in DNA repair pathway genes.,[],0,0,0,1,set(),set(),set(),set(),set(),"{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","
    Context information is below.
    ---------------------
    ['If a prostate cancer patient has a somatic variant in gene RAD54L, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51D, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51B, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRIP1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene PALB2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51C, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BARD1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene FANCL, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: Are PARP inhibitors used for patients with leiomyosarcoma who have mutations in DNA damage repair genes?
     
    ","
    Context information is below.
    ---------------------
    ['If a prostate cancer patient has a somatic variant in gene RAD54L, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51D, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51B, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRIP1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene PALB2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51C, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BARD1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene FANCL, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: Are PARP inhibitors used for patients with leiomyosarcoma who have mutations in DNA damage repair genes?
     
    ","
    Context information is below.
    ---------------------
    ['If a prostate cancer patient has a somatic variant in gene RAD54L, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51D, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51B, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRIP1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene PALB2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51C, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BARD1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene FANCL, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: Are PARP inhibitors used for patients with leiomyosarcoma who have mutations in DNA damage repair genes?
     
    ","
    Context information is below.
    ---------------------
    ['If a prostate cancer patient has a somatic variant in gene RAD54L, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51D, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51B, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRIP1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene PALB2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51C, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BARD1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene FANCL, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: Are PARP inhibitors used for patients with leiomyosarcoma who have mutations in DNA damage repair genes?
     
    ","
    Context information is below.
    ---------------------
    ['If a prostate cancer patient has a somatic variant in gene RAD54L, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51D, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51B, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRIP1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene PALB2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene RAD51C, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BARD1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene FANCL, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: Are PARP inhibitors used for patients with leiomyosarcoma who have mutations in DNA damage repair genes?
     
    "
q2,Are ALK inhibitors approved for use in TFCP2 fusion positive rhabdomyosarcoma?,True,True,"given disease and biomarker, return drugs",False,"No, no ALK inhibitors are currently approved for use for the treatment of patients with rhabdomyosarcoma, nevermind TFCP2 fusion positive rhabdomyosarcoma.",[],0,0,0,1,set(),set(),set(),set(),set(),"{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","
    Context information is below.
    ---------------------
    ['If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: Are ALK inhibitors approved for use in TFCP2 fusion positive rhabdomyosarcoma?
     
    ","
    Context information is below.
    ---------------------
    ['If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: Are ALK inhibitors approved for use in TFCP2 fusion positive rhabdomyosarcoma?
     
    ","
    Context information is below.
    ---------------------
    ['If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: Are ALK inhibitors approved for use in TFCP2 fusion positive rhabdomyosarcoma?
     
    ","
    Context information is below.
    ---------------------
    ['If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: Are ALK inhibitors approved for use in TFCP2 fusion positive rhabdomyosarcoma?
     
    ","
    Context information is below.
    ---------------------
    ['If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: Are ALK inhibitors approved for use in TFCP2 fusion positive rhabdomyosarcoma?
     
    "
q3,"For a patient with cancer metastatic prostate cancer, advanced stage (most often stage IV, but some stage III or earlier potentially) and with BRCA2 mutation, what drugs approved?",True,True,"given disease and biomarker, return drugs",True,"The following therapy and combination therapies are approved by the US FDA for use for the treatment of patients with BRCA2 mutated metastatic castration resistant prostate cancer: olaparib; abiraterone, olaparib, and prednisone; enzalutamide and talazoparib; abiraterone acetate and niraparib; and rucaparib.","[{'olaparib'}, {'prednisone', 'olaparib', 'abiraterone'}, {'talazoparib', 'enzalutamide'}, {'abiraterone acetate', 'niraparib'}, {'rucaparib'}]",3,2,0,0,"{frozenset({'niraparib', 'abiraterone acetate'}), frozenset({'olaparib', 'prednisone', 'abiraterone'}), frozenset({'olaparib'})}","{frozenset({'niraparib', 'abiraterone acetate'}), frozenset({'olaparib', 'prednisone', 'abiraterone'}), frozenset({'olaparib'})}","{frozenset({'niraparib', 'abiraterone acetate'}), frozenset({'olaparib', 'prednisone', 'abiraterone'}), frozenset({'olaparib'})}","{frozenset({'niraparib', 'abiraterone acetate'}), frozenset({'olaparib', 'prednisone', 'abiraterone'}), frozenset({'olaparib'})}","{frozenset({'niraparib', 'abiraterone acetate'}), frozenset({'olaparib', 'prednisone', 'abiraterone'}), frozenset({'olaparib'})}","{
    ""Status"": ""success"",
    ""Treatment 1"": {
        ""Disease Name"": ""Metastatic Prostate Cancer"",
        ""Disease Phase or Condition"": ""Metastatic Castration-Resistant"",
        ""Drug Name"": ""Abiraterone + Prednisone + Olaparib"",
        ""Prior Treatment or Resistance Status"": ""Not specified"",
        ""Genomic Features"": ""BRCA2 mutation (somatic or germline)"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf""
    },
    ""Treatment 2"": {
        ""Disease Name"": ""Metastatic Prostate Cancer"",
        ""Disease Phase or Condition"": ""Metastatic Castration-Resistant"",
        ""Drug Name"": ""Olaparib"",
        ""Prior Treatment or Resistance Status"": ""Progressed following prior treatment with enzalutamide or abiraterone"",
        ""Genomic Features"": ""BRCA2 mutation (somatic or germline)"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf""
    },
    ""Treatment 3"": {
        ""Disease Name"": ""Metastatic Prostate Cancer"",
        ""Disease Phase or Condition"": ""Metastatic Castration-Resistant"",
        ""Drug Name"": ""Abiraterone acetate + Niraparib"",
        ""Prior Treatment or Resistance Status"": ""Not specified"",
        ""Genomic Features"": ""BRCA2 mutation (somatic or germline)"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf""
    }
}","{
    ""Status"": ""success"",
    ""Treatment 1"": {
        ""Disease Name"": ""Metastatic Prostate Cancer"",
        ""Disease Phase or Condition"": ""Metastatic Castration-Resistant"",
        ""Drug Name"": ""Abiraterone + Prednisone + Olaparib"",
        ""Prior Treatment or Resistance Status"": ""Not specified"",
        ""Genomic Features"": ""BRCA2 mutation (somatic or germline)"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf""
    },
    ""Treatment 2"": {
        ""Disease Name"": ""Metastatic Prostate Cancer"",
        ""Disease Phase or Condition"": ""Metastatic Castration-Resistant"",
        ""Drug Name"": ""Olaparib"",
        ""Prior Treatment or Resistance Status"": ""Progressed following prior treatment with enzalutamide or abiraterone"",
        ""Genomic Features"": ""BRCA2 mutation (somatic or germline)"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf""
    },
    ""Treatment 3"": {
        ""Disease Name"": ""Metastatic Prostate Cancer"",
        ""Disease Phase or Condition"": ""Metastatic Castration-Resistant"",
        ""Drug Name"": ""Abiraterone acetate + Niraparib"",
        ""Prior Treatment or Resistance Status"": ""Not specified"",
        ""Genomic Features"": ""BRCA2 mutation (somatic or germline)"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf""
    }
}","{
    ""Status"": ""success"",
    ""Treatment 1"": {
        ""Disease Name"": ""Metastatic Prostate Cancer"",
        ""Disease Phase or Condition"": ""Metastatic Castration-Resistant"",
        ""Drug Name"": ""Abiraterone + Prednisone + Olaparib"",
        ""Prior Treatment or Resistance Status"": ""Not specified"",
        ""Genomic Features"": ""BRCA2 mutation (somatic or germline)"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf""
    },
    ""Treatment 2"": {
        ""Disease Name"": ""Metastatic Prostate Cancer"",
        ""Disease Phase or Condition"": ""Metastatic Castration-Resistant"",
        ""Drug Name"": ""Olaparib"",
        ""Prior Treatment or Resistance Status"": ""Progressed following prior treatment with enzalutamide or abiraterone"",
        ""Genomic Features"": ""BRCA2 mutation (somatic or germline)"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf""
    },
    ""Treatment 3"": {
        ""Disease Name"": ""Metastatic Prostate Cancer"",
        ""Disease Phase or Condition"": ""Metastatic Castration-Resistant"",
        ""Drug Name"": ""Abiraterone acetate + Niraparib"",
        ""Prior Treatment or Resistance Status"": ""Not specified"",
        ""Genomic Features"": ""BRCA2 mutation (somatic or germline)"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf""
    }
}","{
    ""Status"": ""success"",
    ""Treatment 1"": {
        ""Disease Name"": ""Metastatic Prostate Cancer"",
        ""Disease Phase or Condition"": ""Metastatic Castration-Resistant Prostate Cancer (mCRPC)"",
        ""Drug Name"": ""Abiraterone + Prednisone + Olaparib"",
        ""Prior Treatment or Resistance Status"": ""Not specified"",
        ""Genomic Features"": ""BRCA2 mutation (germline or somatic)"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf""
    },
    ""Treatment 2"": {
        ""Disease Name"": ""Metastatic Prostate Cancer"",
        ""Disease Phase or Condition"": ""Metastatic Castration-Resistant Prostate Cancer (mCRPC)"",
        ""Drug Name"": ""Olaparib"",
        ""Prior Treatment or Resistance Status"": ""Progressed following prior treatment with enzalutamide or abiraterone"",
        ""Genomic Features"": ""BRCA2 mutation (germline or somatic)"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf""
    },
    ""Treatment 3"": {
        ""Disease Name"": ""Metastatic Prostate Cancer"",
        ""Disease Phase or Condition"": ""Metastatic Castration-Resistant Prostate Cancer (mCRPC)"",
        ""Drug Name"": ""Abiraterone acetate + Niraparib"",
        ""Prior Treatment or Resistance Status"": ""Not specified"",
        ""Genomic Features"": ""BRCA2 mutation (germline or somatic)"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf""
    }
}","{
    ""Status"": ""success"",
    ""Treatment 1"": {
        ""Disease Name"": ""Metastatic Prostate Cancer"",
        ""Disease Phase or Condition"": ""Metastatic Castration-Resistant Prostate Cancer (mCRPC)"",
        ""Drug Name"": ""Abiraterone + Prednisone + Olaparib"",
        ""Prior Treatment or Resistance Status"": ""Not specified"",
        ""Genomic Features"": ""BRCA2 mutation (germline or somatic)"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf""
    },
    ""Treatment 2"": {
        ""Disease Name"": ""Metastatic Prostate Cancer"",
        ""Disease Phase or Condition"": ""Metastatic Castration-Resistant Prostate Cancer (mCRPC)"",
        ""Drug Name"": ""Olaparib"",
        ""Prior Treatment or Resistance Status"": ""Progressed following prior treatment with enzalutamide or abiraterone"",
        ""Genomic Features"": ""BRCA2 mutation (germline or somatic)"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf""
    },
    ""Treatment 3"": {
        ""Disease Name"": ""Metastatic Prostate Cancer"",
        ""Disease Phase or Condition"": ""Metastatic Castration-Resistant Prostate Cancer (mCRPC)"",
        ""Drug Name"": ""Abiraterone acetate + Niraparib"",
        ""Prior Treatment or Resistance Status"": ""Not specified"",
        ""Genomic Features"": ""BRCA2 mutation (germline or somatic)"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf""
    }
}","
    Context information is below.
    ---------------------
    ['If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: For a patient with cancer metastatic prostate cancer, advanced stage (most often stage IV, but some stage III or earlier potentially) and with BRCA2 mutation, what drugs approved?
     
    ","
    Context information is below.
    ---------------------
    ['If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: For a patient with cancer metastatic prostate cancer, advanced stage (most often stage IV, but some stage III or earlier potentially) and with BRCA2 mutation, what drugs approved?
     
    ","
    Context information is below.
    ---------------------
    ['If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: For a patient with cancer metastatic prostate cancer, advanced stage (most often stage IV, but some stage III or earlier potentially) and with BRCA2 mutation, what drugs approved?
     
    ","
    Context information is below.
    ---------------------
    ['If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: For a patient with cancer metastatic prostate cancer, advanced stage (most often stage IV, but some stage III or earlier potentially) and with BRCA2 mutation, what drugs approved?
     
    ","
    Context information is below.
    ---------------------
    ['If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone acetate + Niraparib. The U.S. Food and Drug Administration (FDA) granted approval to niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and abiraterone acetate, a CYP17 inhibitor indicated with prednisone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: Janssen Biotech, Inc. Akeega (niraparib and abiraterone acetate) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA2, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a somatic variant in gene BRCA1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a prostate cancer patient has a germline variant in gene BRCA1, and is metastatic castration-resistant, one recommended treatment would be Abiraterone + Prednisone + Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: For a patient with cancer metastatic prostate cancer, advanced stage (most often stage IV, but some stage III or earlier potentially) and with BRCA2 mutation, what drugs approved?
     
    "
q4,"For a patient with HER2+ breast cancer after neoadjvuant chemotherapy + trastuzumab then surgery, if residual disease at time of surgery, what treatment options are approved afterwards?",True,True,"given disease and biomarker, return drugs; HER2-related",True,TDM-1 (ado-trastuzumab emtansine (Kadcyla)),[{'ado-trastuzumab emtansine'}],1,0,0,0,{frozenset({'ado-trastuzumab emtansine'})},{frozenset({'ado-trastuzumab emtansine'})},{frozenset({'ado-trastuzumab emtansine'})},{frozenset({'ado-trastuzumab emtansine'})},{frozenset({'ado-trastuzumab emtansine'})},"{
    ""Status"": ""success"",
    ""Treatment 1"": {
        ""Disease Name"": ""HER2-positive breast cancer"",
        ""Disease Phase or Condition"": ""Residual disease after neoadjuvant chemotherapy and trastuzumab followed by surgery"",
        ""Drug Name"": ""Ado-Trastuzumab Emtansine"",
        ""Prior Treatment or Resistance Status"": ""Received prior therapy for metastatic disease or developed disease recurrence during or within six months of completing adjuvant therapy"",
        ""Genomic Features"": ""HER2-positive"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf""
    }
}","{
    ""Status"": ""success"",
    ""Treatment 1"": {
        ""Disease Name"": ""HER2-positive breast cancer"",
        ""Disease Phase or Condition"": ""Residual disease after neoadjuvant chemotherapy and trastuzumab followed by surgery"",
        ""Drug Name"": ""Ado-Trastuzumab Emtansine"",
        ""Prior Treatment or Resistance Status"": ""Received prior therapy for metastatic disease or developed disease recurrence during or within six months of completing adjuvant therapy"",
        ""Genomic Features"": ""HER2-positive"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf""
    }
}","{
    ""Status"": ""success"",
    ""Treatment 1"": {
        ""Disease Name"": ""HER2-positive breast cancer"",
        ""Disease Phase or Condition"": ""Residual disease after neoadjuvant chemotherapy and trastuzumab followed by surgery"",
        ""Drug Name"": ""Ado-Trastuzumab Emtansine"",
        ""Prior Treatment or Resistance Status"": ""Received prior therapy for metastatic disease or developed disease recurrence during or within six months of completing adjuvant therapy"",
        ""Genomic Features"": ""HER2-positive"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf""
    }
}","{
    ""Status"": ""success"",
    ""Treatment 1"": {
        ""Disease Name"": ""HER2-positive breast cancer"",
        ""Disease Phase or Condition"": ""Residual disease after neoadjuvant chemotherapy and trastuzumab followed by surgery"",
        ""Drug Name"": ""Ado-Trastuzumab Emtansine"",
        ""Prior Treatment or Resistance Status"": ""Received prior therapy for metastatic disease or developed disease recurrence during or within six months of completing adjuvant therapy"",
        ""Genomic Features"": ""HER2-positive"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf""
    }
}","{
    ""Status"": ""success"",
    ""Treatment 1"": {
        ""Disease Name"": ""HER2-positive breast cancer"",
        ""Disease Phase or Condition"": ""Residual disease after neoadjuvant chemotherapy and trastuzumab followed by surgery"",
        ""Drug Name"": ""Ado-Trastuzumab Emtansine"",
        ""Prior Treatment or Resistance Status"": ""Received prior therapy for metastatic disease or developed disease recurrence during or within six months of completing adjuvant therapy"",
        ""Genomic Features"": ""HER2-positive"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf""
    }
}","
    Context information is below.
    ---------------------
    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing breast cancer. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is locally advanced, inflammatory, or early stage, one recommended treatment would be Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with chemotherapy for the following indications: neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Lapatinib + Trastuzumab. Lapatinib is a kinase inhibitor indicated in combination with: (1) capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Limitations of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib in combination with capecitabine. (2) letrozole for the treatment of postmenopausal women with hormone receptorpositive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. (Citation: Novartis Pharmaceuticals Corporation. Tykerb (lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s024lbl.pdf. Revised December 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with docetaxel for treatment of patients with HER-2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: For a patient with HER2+ breast cancer after neoadjvuant chemotherapy + trastuzumab then surgery, if residual disease at time of surgery, what treatment options are approved afterwards?
     
    ","
    Context information is below.
    ---------------------
    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing breast cancer. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is locally advanced, inflammatory, or early stage, one recommended treatment would be Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with chemotherapy for the following indications: neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Lapatinib + Trastuzumab. Lapatinib is a kinase inhibitor indicated in combination with: (1) capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Limitations of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib in combination with capecitabine. (2) letrozole for the treatment of postmenopausal women with hormone receptorpositive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. (Citation: Novartis Pharmaceuticals Corporation. Tykerb (lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s024lbl.pdf. Revised December 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with docetaxel for treatment of patients with HER-2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: For a patient with HER2+ breast cancer after neoadjvuant chemotherapy + trastuzumab then surgery, if residual disease at time of surgery, what treatment options are approved afterwards?
     
    ","
    Context information is below.
    ---------------------
    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing breast cancer. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is locally advanced, inflammatory, or early stage, one recommended treatment would be Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with chemotherapy for the following indications: neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Lapatinib + Trastuzumab. Lapatinib is a kinase inhibitor indicated in combination with: (1) capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Limitations of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib in combination with capecitabine. (2) letrozole for the treatment of postmenopausal women with hormone receptorpositive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. (Citation: Novartis Pharmaceuticals Corporation. Tykerb (lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s024lbl.pdf. Revised December 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with docetaxel for treatment of patients with HER-2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: For a patient with HER2+ breast cancer after neoadjvuant chemotherapy + trastuzumab then surgery, if residual disease at time of surgery, what treatment options are approved afterwards?
     
    ","
    Context information is below.
    ---------------------
    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing breast cancer. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is locally advanced, inflammatory, or early stage, one recommended treatment would be Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with chemotherapy for the following indications: neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Lapatinib + Trastuzumab. Lapatinib is a kinase inhibitor indicated in combination with: (1) capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Limitations of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib in combination with capecitabine. (2) letrozole for the treatment of postmenopausal women with hormone receptorpositive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. (Citation: Novartis Pharmaceuticals Corporation. Tykerb (lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s024lbl.pdf. Revised December 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with docetaxel for treatment of patients with HER-2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: For a patient with HER2+ breast cancer after neoadjvuant chemotherapy + trastuzumab then surgery, if residual disease at time of surgery, what treatment options are approved afterwards?
     
    ","
    Context information is below.
    ---------------------
    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing breast cancer. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is locally advanced, inflammatory, or early stage, one recommended treatment would be Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with chemotherapy for the following indications: neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Lapatinib + Trastuzumab. Lapatinib is a kinase inhibitor indicated in combination with: (1) capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Limitations of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib in combination with capecitabine. (2) letrozole for the treatment of postmenopausal women with hormone receptorpositive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. (Citation: Novartis Pharmaceuticals Corporation. Tykerb (lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s024lbl.pdf. Revised December 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with docetaxel for treatment of patients with HER-2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: For a patient with HER2+ breast cancer after neoadjvuant chemotherapy + trastuzumab then surgery, if residual disease at time of surgery, what treatment options are approved afterwards?
     
    "
q5,"For patients with advanced cancer and with NTRK fusions, regardless of cancer types, are there drugs approved?",True,True,"given disease and biomarker, return drugs",True,"Yes, the TRK inhibitors Entrectinib and Larotrectinib are approved for use for the treatment of patients with any solid tumor harboring an NTRK1/2/3 fusion. Repotrectinib was also approved after the release of the version of MOAlamanc used in the study.","[{'entrectinib'}, {'larotrectinib'}]",2,0,0,0,"{frozenset({'larotrectinib'}), frozenset({'entrectinib'})}","{frozenset({'larotrectinib'}), frozenset({'entrectinib'})}","{frozenset({'larotrectinib'}), frozenset({'entrectinib'})}","{frozenset({'larotrectinib'}), frozenset({'entrectinib'})}","{frozenset({'larotrectinib'}), frozenset({'entrectinib'})}","{
    ""Status"": ""success"",
    ""Treatment 1"": {
        ""Disease Name"": ""Solid Tumors"",
        ""Disease Phase or Condition"": ""Advanced or Metastatic"",
        ""Drug Name"": ""Larotrectinib"",
        ""Prior Treatment or Resistance Status"": ""No known resistance mechanism, no satisfactory alternative treatments or have progressed following treatment"",
        ""Genomic Features"": ""NTRK gene fusions"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf""
    },
    ""Treatment 2"": {
        ""Disease Name"": ""Solid Tumors"",
        ""Disease Phase or Condition"": ""Advanced or Metastatic"",
        ""Drug Name"": ""Entrectinib"",
        ""Prior Treatment or Resistance Status"": ""No known acquired resistance mutation, have progressed following treatment or have no satisfactory standard therapy"",
        ""Genomic Features"": ""NTRK gene fusions"",
        ""FDA-approval status"": ""Accelerated Approval"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf""
    }
}","{
    ""Status"": ""success"",
    ""Treatment 1"": {
        ""Disease Name"": ""Solid Tumors"",
        ""Disease Phase or Condition"": ""Advanced or Metastatic"",
        ""Drug Name"": ""Larotrectinib"",
        ""Prior Treatment or Resistance Status"": ""No known resistance mechanism, no satisfactory alternative treatments or have progressed following treatment"",
        ""Genomic Features"": ""NTRK gene fusions"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf""
    },
    ""Treatment 2"": {
        ""Disease Name"": ""Solid Tumors"",
        ""Disease Phase or Condition"": ""Advanced or Metastatic"",
        ""Drug Name"": ""Entrectinib"",
        ""Prior Treatment or Resistance Status"": ""No known acquired resistance mutation, have progressed following treatment or have no satisfactory standard therapy"",
        ""Genomic Features"": ""NTRK gene fusions"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf""
    }
}","{
    ""Status"": ""success"",
    ""Treatment 1"": {
        ""Disease Name"": ""Solid Tumors"",
        ""Disease Phase or Condition"": ""Advanced or Metastatic"",
        ""Drug Name"": ""Larotrectinib"",
        ""Prior Treatment or Resistance Status"": ""No known resistance mechanism, no satisfactory alternative treatments or have progressed following treatment"",
        ""Genomic Features"": ""NTRK gene fusions"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf""
    },
    ""Treatment 2"": {
        ""Disease Name"": ""Solid Tumors"",
        ""Disease Phase or Condition"": ""Advanced or Metastatic"",
        ""Drug Name"": ""Entrectinib"",
        ""Prior Treatment or Resistance Status"": ""No known acquired resistance mutation, have progressed following treatment or have no satisfactory standard therapy"",
        ""Genomic Features"": ""NTRK gene fusions"",
        ""FDA-approval status"": ""Accelerated Approval"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf""
    }
}","{
    ""Status"": ""success"",
    ""Treatment 1"": {
        ""Disease Name"": ""Solid Tumors"",
        ""Disease Phase or Condition"": ""Advanced or Metastatic"",
        ""Drug Name"": ""Larotrectinib"",
        ""Prior Treatment or Resistance Status"": ""No known resistance mechanism, no satisfactory alternative treatments or have progressed following treatment"",
        ""Genomic Features"": ""NTRK gene fusions"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf""
    },
    ""Treatment 2"": {
        ""Disease Name"": ""Solid Tumors"",
        ""Disease Phase or Condition"": ""Advanced or Metastatic"",
        ""Drug Name"": ""Entrectinib"",
        ""Prior Treatment or Resistance Status"": ""No known acquired resistance mutation, have progressed following treatment or have no satisfactory standard therapy"",
        ""Genomic Features"": ""NTRK gene fusions"",
        ""FDA-approval status"": ""Accelerated Approval"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf""
    }
}","{
    ""Status"": ""success"",
    ""Treatment 1"": {
        ""Disease Name"": ""Solid Tumors"",
        ""Disease Phase or Condition"": ""Advanced or Metastatic"",
        ""Drug Name"": ""Larotrectinib"",
        ""Prior Treatment or Resistance Status"": ""No known resistance mechanism, no satisfactory alternative treatments or have progressed following treatment"",
        ""Genomic Features"": ""NTRK gene fusions"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf""
    },
    ""Treatment 2"": {
        ""Disease Name"": ""Solid Tumors"",
        ""Disease Phase or Condition"": ""Advanced or Metastatic"",
        ""Drug Name"": ""Entrectinib"",
        ""Prior Treatment or Resistance Status"": ""No known acquired resistance mutation, no satisfactory standard therapy or have progressed following treatment"",
        ""Genomic Features"": ""NTRK gene fusions"",
        ""FDA-approval status"": ""Accelerated Approval"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf""
    }
}","
    Context information is below.
    ---------------------
    ['If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Pralsetinib. The U.S. Food and Drug Administration granted accelerated approval to pralsetinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy or who are radioactive iodine-refractory (if radioactive iodine is appropriate). (Citation: Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a non-small cell lung cancer patient has a rearrangement in gene RET, and is metastatic, one recommended treatment would be Pralsetinib. The U.S. Food and Drug Administration (FDA) granted regular approval for pralsetinib for adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. (Citation: Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refactory (if radioactive iodine is appropriate). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene RET, and is metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: For patients with advanced cancer and with NTRK fusions, regardless of cancer types, are there drugs approved?
     
    ","
    Context information is below.
    ---------------------
    ['If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Pralsetinib. The U.S. Food and Drug Administration granted accelerated approval to pralsetinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy or who are radioactive iodine-refractory (if radioactive iodine is appropriate). (Citation: Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a non-small cell lung cancer patient has a rearrangement in gene RET, and is metastatic, one recommended treatment would be Pralsetinib. The U.S. Food and Drug Administration (FDA) granted regular approval for pralsetinib for adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. (Citation: Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refactory (if radioactive iodine is appropriate). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene RET, and is metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: For patients with advanced cancer and with NTRK fusions, regardless of cancer types, are there drugs approved?
     
    ","
    Context information is below.
    ---------------------
    ['If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Pralsetinib. The U.S. Food and Drug Administration granted accelerated approval to pralsetinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy or who are radioactive iodine-refractory (if radioactive iodine is appropriate). (Citation: Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a non-small cell lung cancer patient has a rearrangement in gene RET, and is metastatic, one recommended treatment would be Pralsetinib. The U.S. Food and Drug Administration (FDA) granted regular approval for pralsetinib for adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. (Citation: Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refactory (if radioactive iodine is appropriate). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene RET, and is metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: For patients with advanced cancer and with NTRK fusions, regardless of cancer types, are there drugs approved?
     
    ","
    Context information is below.
    ---------------------
    ['If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Pralsetinib. The U.S. Food and Drug Administration granted accelerated approval to pralsetinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy or who are radioactive iodine-refractory (if radioactive iodine is appropriate). (Citation: Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a non-small cell lung cancer patient has a rearrangement in gene RET, and is metastatic, one recommended treatment would be Pralsetinib. The U.S. Food and Drug Administration (FDA) granted regular approval for pralsetinib for adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. (Citation: Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refactory (if radioactive iodine is appropriate). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene RET, and is metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: For patients with advanced cancer and with NTRK fusions, regardless of cancer types, are there drugs approved?
     
    ","
    Context information is below.
    ---------------------
    ['If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Pralsetinib. The U.S. Food and Drug Administration granted accelerated approval to pralsetinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy or who are radioactive iodine-refractory (if radioactive iodine is appropriate). (Citation: Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a non-small cell lung cancer patient has a rearrangement in gene RET, and is metastatic, one recommended treatment would be Pralsetinib. The U.S. Food and Drug Administration (FDA) granted regular approval for pralsetinib for adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. (Citation: Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refactory (if radioactive iodine is appropriate). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene RET, and is metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: For patients with advanced cancer and with NTRK fusions, regardless of cancer types, are there drugs approved?
     
    "
q6,"For patients with advanced cancer and with high TMB, regardless of cancer types, are there drugs approved?",True,True,"given disease and biomarker, return drugs",True,"Yes, Keytruda (pembrolizumab) is approved by the FDA for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>=10 mutations/megabase (mut/Mb)] solid tumors.",[{'pembrolizumab'}],1,0,0,0,{frozenset({'pembrolizumab'})},{frozenset({'pembrolizumab'})},{frozenset({'pembrolizumab'})},{frozenset({'pembrolizumab'})},{frozenset({'pembrolizumab'})},"{
    ""Status"": ""success"",
    ""Treatment 1"": {
        ""Disease Name"": ""Solid Tumors"",
        ""Disease Phase or Condition"": ""Unresectable or Metastatic"",
        ""Drug Name"": ""Pembrolizumab"",
        ""Prior Treatment or Resistance Status"": ""Progressed following prior treatment and who have no satisfactory alternative treatment options"",
        ""Genomic Features"": ""High Tumor Mutational Burden (TMB-H) [>= 10 mutations/megabase (mut/Mb)]"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf""
    }
}","{
    ""Status"": ""success"",
    ""Treatment 1"": {
        ""Disease Name"": ""Solid Tumors"",
        ""Disease Phase or Condition"": ""Unresectable or Metastatic"",
        ""Drug Name"": ""Pembrolizumab"",
        ""Prior Treatment or Resistance Status"": ""Progressed following prior treatment and who have no satisfactory alternative treatment options"",
        ""Genomic Features"": ""High Tumor Mutational Burden (TMB-H) [>= 10 mutations/megabase (mut/Mb)]"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf""
    }
}","{
    ""Status"": ""success"",
    ""Treatment 1"": {
        ""Disease Name"": ""Solid Tumors"",
        ""Disease Phase or Condition"": ""Unresectable or Metastatic"",
        ""Drug Name"": ""Pembrolizumab"",
        ""Prior Treatment or Resistance Status"": ""Progressed following prior treatment and who have no satisfactory alternative treatment options"",
        ""Genomic Features"": ""High Tumor Mutational Burden (TMB-H) [>= 10 mutations/megabase (mut/Mb)]"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf""
    }
}","{
    ""Status"": ""success"",
    ""Treatment 1"": {
        ""Disease Name"": ""Solid Tumors"",
        ""Disease Phase or Condition"": ""Unresectable or Metastatic"",
        ""Drug Name"": ""Pembrolizumab"",
        ""Prior Treatment or Resistance Status"": ""Progressed following prior treatment and who have no satisfactory alternative treatment options"",
        ""Genomic Features"": ""High Tumor Mutational Burden (TMB-H) [>= 10 mutations/megabase (mut/Mb)]"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf""
    }
}","{
    ""Status"": ""success"",
    ""Treatment 1"": {
        ""Disease Name"": ""Solid Tumors"",
        ""Disease Phase or Condition"": ""Unresectable or Metastatic"",
        ""Drug Name"": ""Pembrolizumab"",
        ""Prior Treatment or Resistance Status"": ""Progressed following prior treatment and who have no satisfactory alternative treatment options"",
        ""Genomic Features"": ""High Tumor Mutational Burden (TMB-H) [>= 10 mutations/megabase (mut/Mb)]"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf""
    }
}","
    Context information is below.
    ---------------------
    ['If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a endometrial carcinoma patient is MSI-high, and is advanced, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal ca (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a colorectal cancer patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a non-small cell lung cancer patient has a somatic variant in gene MET (exon 14 splice site), and is metastatic, one recommended treatment would be Tepotinib. The U.S. Food and Drug Administration (FDA) granted traditional approval to tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer whose tumors harbor MET exon 14 skipping alterations. (Citation: EMD Serono, Inc. Tepmetko (tepotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214096s003lbl.pdf. Revised February 2024. Accessed March 4, 2024.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a non-small cell lung cancer patient has a somatic variant in gene MET (exon 14 deletion), and is metastatic, one recommended treatment would be Tepotinib. The U.S. Food and Drug Administration (FDA) granted traditional approval to tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer whose tumors harbor MET exon 14 skipping alterations. (Citation: EMD Serono, Inc. Tepmetko (tepotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214096s003lbl.pdf. Revised February 2024. Accessed March 4, 2024.).', 'If a non-small cell lung cancer patient has a somatic variant in gene MET (exon 14 splice site), and is metastatic, one recommended treatment would be Capmatinib. The U.S. Food and Drug Administration (FDA) granted approval to capmatinib for adult patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Tabrecta (capmatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213591s004lbl.pdf. Revised August 2022. Accessed March 4, 2024.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: For patients with advanced cancer and with high TMB, regardless of cancer types, are there drugs approved?
     
    ","
    Context information is below.
    ---------------------
    ['If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a endometrial carcinoma patient is MSI-high, and is advanced, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal ca (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a colorectal cancer patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a non-small cell lung cancer patient has a somatic variant in gene MET (exon 14 splice site), and is metastatic, one recommended treatment would be Tepotinib. The U.S. Food and Drug Administration (FDA) granted traditional approval to tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer whose tumors harbor MET exon 14 skipping alterations. (Citation: EMD Serono, Inc. Tepmetko (tepotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214096s003lbl.pdf. Revised February 2024. Accessed March 4, 2024.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a non-small cell lung cancer patient has a somatic variant in gene MET (exon 14 deletion), and is metastatic, one recommended treatment would be Tepotinib. The U.S. Food and Drug Administration (FDA) granted traditional approval to tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer whose tumors harbor MET exon 14 skipping alterations. (Citation: EMD Serono, Inc. Tepmetko (tepotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214096s003lbl.pdf. Revised February 2024. Accessed March 4, 2024.).', 'If a non-small cell lung cancer patient has a somatic variant in gene MET (exon 14 splice site), and is metastatic, one recommended treatment would be Capmatinib. The U.S. Food and Drug Administration (FDA) granted approval to capmatinib for adult patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Tabrecta (capmatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213591s004lbl.pdf. Revised August 2022. Accessed March 4, 2024.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: For patients with advanced cancer and with high TMB, regardless of cancer types, are there drugs approved?
     
    ","
    Context information is below.
    ---------------------
    ['If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a endometrial carcinoma patient is MSI-high, and is advanced, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal ca (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a colorectal cancer patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a non-small cell lung cancer patient has a somatic variant in gene MET (exon 14 splice site), and is metastatic, one recommended treatment would be Tepotinib. The U.S. Food and Drug Administration (FDA) granted traditional approval to tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer whose tumors harbor MET exon 14 skipping alterations. (Citation: EMD Serono, Inc. Tepmetko (tepotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214096s003lbl.pdf. Revised February 2024. Accessed March 4, 2024.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a non-small cell lung cancer patient has a somatic variant in gene MET (exon 14 deletion), and is metastatic, one recommended treatment would be Tepotinib. The U.S. Food and Drug Administration (FDA) granted traditional approval to tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer whose tumors harbor MET exon 14 skipping alterations. (Citation: EMD Serono, Inc. Tepmetko (tepotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214096s003lbl.pdf. Revised February 2024. Accessed March 4, 2024.).', 'If a non-small cell lung cancer patient has a somatic variant in gene MET (exon 14 splice site), and is metastatic, one recommended treatment would be Capmatinib. The U.S. Food and Drug Administration (FDA) granted approval to capmatinib for adult patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Tabrecta (capmatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213591s004lbl.pdf. Revised August 2022. Accessed March 4, 2024.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: For patients with advanced cancer and with high TMB, regardless of cancer types, are there drugs approved?
     
    ","
    Context information is below.
    ---------------------
    ['If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a endometrial carcinoma patient is MSI-high, and is advanced, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal ca (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a colorectal cancer patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a non-small cell lung cancer patient has a somatic variant in gene MET (exon 14 splice site), and is metastatic, one recommended treatment would be Tepotinib. The U.S. Food and Drug Administration (FDA) granted traditional approval to tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer whose tumors harbor MET exon 14 skipping alterations. (Citation: EMD Serono, Inc. Tepmetko (tepotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214096s003lbl.pdf. Revised February 2024. Accessed March 4, 2024.).', 'If a non-small cell lung cancer patient has a somatic variant in gene MET (exon 14 deletion), and is metastatic, one recommended treatment would be Tepotinib. The U.S. Food and Drug Administration (FDA) granted traditional approval to tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer whose tumors harbor MET exon 14 skipping alterations. (Citation: EMD Serono, Inc. Tepmetko (tepotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214096s003lbl.pdf. Revised February 2024. Accessed March 4, 2024.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a non-small cell lung cancer patient has a somatic variant in gene MET (exon 14 splice site), and is metastatic, one recommended treatment would be Capmatinib. The U.S. Food and Drug Administration (FDA) granted approval to capmatinib for adult patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Tabrecta (capmatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213591s004lbl.pdf. Revised August 2022. Accessed March 4, 2024.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: For patients with advanced cancer and with high TMB, regardless of cancer types, are there drugs approved?
     
    ","
    Context information is below.
    ---------------------
    ['If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a endometrial carcinoma patient is MSI-high, and is advanced, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal ca (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a colorectal cancer patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a non-small cell lung cancer patient has a somatic variant in gene MET (exon 14 splice site), and is metastatic, one recommended treatment would be Tepotinib. The U.S. Food and Drug Administration (FDA) granted traditional approval to tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer whose tumors harbor MET exon 14 skipping alterations. (Citation: EMD Serono, Inc. Tepmetko (tepotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214096s003lbl.pdf. Revised February 2024. Accessed March 4, 2024.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a non-small cell lung cancer patient has a somatic variant in gene MET (exon 14 deletion), and is metastatic, one recommended treatment would be Tepotinib. The U.S. Food and Drug Administration (FDA) granted traditional approval to tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer whose tumors harbor MET exon 14 skipping alterations. (Citation: EMD Serono, Inc. Tepmetko (tepotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214096s003lbl.pdf. Revised February 2024. Accessed March 4, 2024.).', 'If a non-small cell lung cancer patient has a somatic variant in gene MET (exon 14 splice site), and is metastatic, one recommended treatment would be Capmatinib. The U.S. Food and Drug Administration (FDA) granted approval to capmatinib for adult patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Tabrecta (capmatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213591s004lbl.pdf. Revised August 2022. Accessed March 4, 2024.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: For patients with advanced cancer and with high TMB, regardless of cancer types, are there drugs approved?
     
    "
q7,What FDA-approved therapies exist for a Stage IV pancreatic ductal adenocarcinoma patient with a NTRK mutation,True,True,"given disease and biomarker, return drugs",True,"While no drugs are approved for use by the US FDA specifically for the treatment of patients with NTRK fusion positive pancreatic adenocarcinoma, a few therapies have received approval for use in any solid tumor that harbors an NTRK fusion. These include: Entrectinib, Larotrectinib. Repotrectinib was also approved after the release of the version of MOAlamanc used in the study.","[{'entrectinib'}, {'larotrectinib'}]",2,0,0,0,"{frozenset({'larotrectinib'}), frozenset({'entrectinib'})}","{frozenset({'larotrectinib'}), frozenset({'entrectinib'})}","{frozenset({'larotrectinib'}), frozenset({'entrectinib'})}","{frozenset({'larotrectinib'}), frozenset({'entrectinib'})}","{frozenset({'larotrectinib'}), frozenset({'entrectinib'})}","{
    ""Status"": ""success"",
    ""Treatment 1"": {
        ""Disease Name"": ""Solid Tumors"",
        ""Disease Phase or Condition"": ""Metastatic or where surgical resection is likely to result in severe morbidity"",
        ""Drug Name"": ""Larotrectinib"",
        ""Prior Treatment or Resistance Status"": ""No satisfactory alternative treatments or have progressed following treatment"",
        ""Genomic Features"": ""NTRK gene fusions without a known resistance mechanism"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf""
    },
    ""Treatment 2"": {
        ""Disease Name"": ""Solid Tumors"",
        ""Disease Phase or Condition"": ""Metastatic or where surgical resection is likely to result in severe morbidity"",
        ""Drug Name"": ""Entrectinib"",
        ""Prior Treatment or Resistance Status"": ""Have progressed following treatment or have no satisfactory standard therapy"",
        ""Genomic Features"": ""NTRK gene fusion without a known acquired resistance mutation"",
        ""FDA-approval status"": ""Accelerated Approval"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf""
    }
}","{
    ""Status"": ""success"",
    ""Treatment 1"": {
        ""Disease Name"": ""Solid Tumors"",
        ""Disease Phase or Condition"": ""Metastatic or where surgical resection is likely to result in severe morbidity"",
        ""Drug Name"": ""Larotrectinib"",
        ""Prior Treatment or Resistance Status"": ""No satisfactory alternative treatments or have progressed following treatment"",
        ""Genomic Features"": ""NTRK gene fusions without a known resistance mechanism"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf""
    },
    ""Treatment 2"": {
        ""Disease Name"": ""Solid Tumors"",
        ""Disease Phase or Condition"": ""Metastatic or where surgical resection is likely to result in severe morbidity"",
        ""Drug Name"": ""Entrectinib"",
        ""Prior Treatment or Resistance Status"": ""Have progressed following treatment or have no satisfactory standard therapy"",
        ""Genomic Features"": ""NTRK gene fusion without a known acquired resistance mutation"",
        ""FDA-approval status"": ""Accelerated Approval"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf""
    }
}","{
    ""Status"": ""success"",
    ""Treatment 1"": {
        ""Disease Name"": ""Solid Tumors"",
        ""Disease Phase or Condition"": ""Metastatic or where surgical resection is likely to result in severe morbidity"",
        ""Drug Name"": ""Larotrectinib"",
        ""Prior Treatment or Resistance Status"": ""No satisfactory alternative treatments or have progressed following treatment"",
        ""Genomic Features"": ""NTRK gene fusions without a known resistance mechanism"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf""
    },
    ""Treatment 2"": {
        ""Disease Name"": ""Solid Tumors"",
        ""Disease Phase or Condition"": ""Metastatic or where surgical resection is likely to result in severe morbidity"",
        ""Drug Name"": ""Entrectinib"",
        ""Prior Treatment or Resistance Status"": ""Have progressed following treatment or have no satisfactory standard therapy"",
        ""Genomic Features"": ""NTRK gene fusion without a known acquired resistance mutation"",
        ""FDA-approval status"": ""Accelerated Approval"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf""
    }
}","{
    ""Status"": ""success"",
    ""Treatment 1"": {
        ""Disease Name"": ""Solid Tumors"",
        ""Disease Phase or Condition"": ""Metastatic or where surgical resection is likely to result in severe morbidity"",
        ""Drug Name"": ""Larotrectinib"",
        ""Prior Treatment or Resistance Status"": ""No satisfactory alternative treatments or have progressed following treatment"",
        ""Genomic Features"": ""NTRK gene fusions without a known resistance mechanism"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf""
    },
    ""Treatment 2"": {
        ""Disease Name"": ""Solid Tumors"",
        ""Disease Phase or Condition"": ""Metastatic or where surgical resection is likely to result in severe morbidity"",
        ""Drug Name"": ""Entrectinib"",
        ""Prior Treatment or Resistance Status"": ""Have progressed following treatment or have no satisfactory standard therapy"",
        ""Genomic Features"": ""NTRK gene fusion without a known acquired resistance mutation"",
        ""FDA-approval status"": ""Accelerated Approval"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf""
    }
}","{
    ""Status"": ""success"",
    ""Treatment 1"": {
        ""Disease Name"": ""Solid Tumors"",
        ""Disease Phase or Condition"": ""Metastatic or where surgical resection is likely to result in severe morbidity"",
        ""Drug Name"": ""Larotrectinib"",
        ""Prior Treatment or Resistance Status"": ""No satisfactory alternative treatments or have progressed following treatment"",
        ""Genomic Features"": ""NTRK gene fusions without a known resistance mechanism"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf""
    },
    ""Treatment 2"": {
        ""Disease Name"": ""Solid Tumors"",
        ""Disease Phase or Condition"": ""Metastatic or where surgical resection is likely to result in severe morbidity"",
        ""Drug Name"": ""Entrectinib"",
        ""Prior Treatment or Resistance Status"": ""Have progressed following treatment or have no satisfactory standard therapy"",
        ""Genomic Features"": ""NTRK gene fusion without a known acquired resistance mutation"",
        ""FDA-approval status"": ""Accelerated Approval"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf""
    }
}","
    Context information is below.
    ---------------------
    ['If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: What FDA-approved therapies exist for a Stage IV pancreatic ductal adenocarcinoma patient with a NTRK mutation
     
    ","
    Context information is below.
    ---------------------
    ['If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: What FDA-approved therapies exist for a Stage IV pancreatic ductal adenocarcinoma patient with a NTRK mutation
     
    ","
    Context information is below.
    ---------------------
    ['If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: What FDA-approved therapies exist for a Stage IV pancreatic ductal adenocarcinoma patient with a NTRK mutation
     
    ","
    Context information is below.
    ---------------------
    ['If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: What FDA-approved therapies exist for a Stage IV pancreatic ductal adenocarcinoma patient with a NTRK mutation
     
    ","
    Context information is below.
    ---------------------
    ['If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: What FDA-approved therapies exist for a Stage IV pancreatic ductal adenocarcinoma patient with a NTRK mutation
     
    "
q8,What are available FDA-approved targeted therapies in patients with FGFR2 mutated bladder cancer? In which disease setting are they approved (metastatic disease only or peri-operative)?,True,True,"given disease and biomarker, return drugs",False,There are not currently approved therapies for use from the US FDA for the treatment of patients with FGFR2 mutated bladder cancer.,[],0,0,0,1,set(),set(),set(),set(),set(),"{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","
    Context information is below.
    ---------------------
    ['If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a intrahepatic cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is locally advanced or metastatic, one recommended treatment would be Futibatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lytgobi (futibatinib) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 rearrangements. (Citation: Taiho Pharmaceutical Co., Ltd. Lytgobi (futibatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf. Revised September 2022. Accessed October 6th, 2022.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR, one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: What are available FDA-approved targeted therapies in patients with FGFR2 mutated bladder cancer? In which disease setting are they approved (metastatic disease only or peri-operative)?
     
    ","
    Context information is below.
    ---------------------
    ['If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a intrahepatic cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is locally advanced or metastatic, one recommended treatment would be Futibatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lytgobi (futibatinib) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 rearrangements. (Citation: Taiho Pharmaceutical Co., Ltd. Lytgobi (futibatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf. Revised September 2022. Accessed October 6th, 2022.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR, one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: What are available FDA-approved targeted therapies in patients with FGFR2 mutated bladder cancer? In which disease setting are they approved (metastatic disease only or peri-operative)?
     
    ","
    Context information is below.
    ---------------------
    ['If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a intrahepatic cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is locally advanced or metastatic, one recommended treatment would be Futibatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lytgobi (futibatinib) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 rearrangements. (Citation: Taiho Pharmaceutical Co., Ltd. Lytgobi (futibatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf. Revised September 2022. Accessed October 6th, 2022.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR, one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: What are available FDA-approved targeted therapies in patients with FGFR2 mutated bladder cancer? In which disease setting are they approved (metastatic disease only or peri-operative)?
     
    ","
    Context information is below.
    ---------------------
    ['If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a intrahepatic cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is locally advanced or metastatic, one recommended treatment would be Futibatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lytgobi (futibatinib) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 rearrangements. (Citation: Taiho Pharmaceutical Co., Ltd. Lytgobi (futibatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf. Revised September 2022. Accessed October 6th, 2022.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR, one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: What are available FDA-approved targeted therapies in patients with FGFR2 mutated bladder cancer? In which disease setting are they approved (metastatic disease only or peri-operative)?
     
    ","
    Context information is below.
    ---------------------
    ['If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a intrahepatic cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is locally advanced or metastatic, one recommended treatment would be Futibatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lytgobi (futibatinib) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 rearrangements. (Citation: Taiho Pharmaceutical Co., Ltd. Lytgobi (futibatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf. Revised September 2022. Accessed October 6th, 2022.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR, one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: What are available FDA-approved targeted therapies in patients with FGFR2 mutated bladder cancer? In which disease setting are they approved (metastatic disease only or peri-operative)?
     
    "
q9,"A patient with localized Ewing sarcoma has a STAG2 mutation, and has just relapsed. What are reasonable relapse regimens to consider?",True,True,"given disease and biomarker, return drugs",False,The US FDA has not yet approved any treatments for use for the treatment of patients with localized or relapsed Ewing sarcoma with STAG2 mutations.,[],0,0,0,1,set(),set(),set(),set(),set(),"{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","
    Context information is below.
    ---------------------
    ['If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT (c.2009C>T or p.T670I), and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT (c.1961T>C or p.V654A), and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT, and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT, and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.2075C>T or p.A692V), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1938C>A or p.Y646*), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a any solid tumor patient has a rearrangement in gene RET, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Retevmo (selpercatinib) for the treatment of adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alterantive treatment options. (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1936T>A or p.Y646N), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1937A>T or p.Y646F), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: A patient with localized Ewing sarcoma has a STAG2 mutation, and has just relapsed. What are reasonable relapse regimens to consider?
     
    ","
    Context information is below.
    ---------------------
    ['If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT (c.2009C>T or p.T670I), and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT (c.1961T>C or p.V654A), and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT, and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT, and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.2075C>T or p.A692V), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1938C>A or p.Y646*), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a any solid tumor patient has a rearrangement in gene RET, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Retevmo (selpercatinib) for the treatment of adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alterantive treatment options. (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1936T>A or p.Y646N), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1937A>T or p.Y646F), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: A patient with localized Ewing sarcoma has a STAG2 mutation, and has just relapsed. What are reasonable relapse regimens to consider?
     
    ","
    Context information is below.
    ---------------------
    ['If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT (c.2009C>T or p.T670I), and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT (c.1961T>C or p.V654A), and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT, and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT, and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.2075C>T or p.A692V), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1938C>A or p.Y646*), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a any solid tumor patient has a rearrangement in gene RET, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Retevmo (selpercatinib) for the treatment of adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alterantive treatment options. (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1936T>A or p.Y646N), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1937A>T or p.Y646F), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: A patient with localized Ewing sarcoma has a STAG2 mutation, and has just relapsed. What are reasonable relapse regimens to consider?
     
    ","
    Context information is below.
    ---------------------
    ['If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT (c.2009C>T or p.T670I), and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT (c.1961T>C or p.V654A), and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT, and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT, and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.2075C>T or p.A692V), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1938C>A or p.Y646*), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a any solid tumor patient has a rearrangement in gene RET, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Retevmo (selpercatinib) for the treatment of adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alterantive treatment options. (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1936T>A or p.Y646N), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1937A>T or p.Y646F), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: A patient with localized Ewing sarcoma has a STAG2 mutation, and has just relapsed. What are reasonable relapse regimens to consider?
     
    ","
    Context information is below.
    ---------------------
    ['If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT (c.2009C>T or p.T670I), and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT (c.1961T>C or p.V654A), and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT, and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a gastrointestinal stromal tumor patient has a somatic variant in gene KIT, and is locally advanced, unresectable or metastatic gastrointestinal stromal tumor (gist) who have been previously treated with imatinib mesylate and sunitinib malate., one recommended treatment would be Regorafenib. FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. (Citation: Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.2075C>T or p.A692V), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1938C>A or p.Y646*), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a any solid tumor patient has a rearrangement in gene RET, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Retevmo (selpercatinib) for the treatment of adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alterantive treatment options. (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1936T>A or p.Y646N), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).', 'If a follicular lymphoma patient has a somatic variant in gene EZH2 (c.1937A>T or p.Y646F), and is relapsed or refractory, one recommended treatment would be Tazemetostat. The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. (Citation: Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: A patient with localized Ewing sarcoma has a STAG2 mutation, and has just relapsed. What are reasonable relapse regimens to consider?
     
    "
q10,"A patient with relapsed high-risk neuroblastoma has ALK mutation X. Should they receive an ALK inhibitor, and if so, which one?",True,True,"given disease and biomarker, return drugs",False,The US FDA has not yet approved any biomarker-based treatments for use for the treatment of patients with neuroblastoma,[],0,0,0,1,set(),set(),set(),set(),set(),"{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","
    Context information is below.
    ---------------------
    ['If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, and is relapsed or refactory, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for adult patients with relapsed or refactory Philidelphia chromosome-positive acute lymphphoblastic leukemia (Ph+ ALL). (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ROS1, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ROS positive metastatic non-small cell lung cancer (NSCLC). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: A patient with relapsed high-risk neuroblastoma has ALK mutation X. Should they receive an ALK inhibitor, and if so, which one?
     
    ","
    Context information is below.
    ---------------------
    ['If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, and is relapsed or refactory, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for adult patients with relapsed or refactory Philidelphia chromosome-positive acute lymphphoblastic leukemia (Ph+ ALL). (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ROS1, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ROS positive metastatic non-small cell lung cancer (NSCLC). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: A patient with relapsed high-risk neuroblastoma has ALK mutation X. Should they receive an ALK inhibitor, and if so, which one?
     
    ","
    Context information is below.
    ---------------------
    ['If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, and is relapsed or refactory, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for adult patients with relapsed or refactory Philidelphia chromosome-positive acute lymphphoblastic leukemia (Ph+ ALL). (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ROS1, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ROS positive metastatic non-small cell lung cancer (NSCLC). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: A patient with relapsed high-risk neuroblastoma has ALK mutation X. Should they receive an ALK inhibitor, and if so, which one?
     
    ","
    Context information is below.
    ---------------------
    ['If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, and is relapsed or refactory, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for adult patients with relapsed or refactory Philidelphia chromosome-positive acute lymphphoblastic leukemia (Ph+ ALL). (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ROS1, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ROS positive metastatic non-small cell lung cancer (NSCLC). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: A patient with relapsed high-risk neuroblastoma has ALK mutation X. Should they receive an ALK inhibitor, and if so, which one?
     
    ","
    Context information is below.
    ---------------------
    ['If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, and is relapsed or refactory, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for adult patients with relapsed or refactory Philidelphia chromosome-positive acute lymphphoblastic leukemia (Ph+ ALL). (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ROS1, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ROS positive metastatic non-small cell lung cancer (NSCLC). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: A patient with relapsed high-risk neuroblastoma has ALK mutation X. Should they receive an ALK inhibitor, and if so, which one?
     
    "
q11,"I have a 3 year old patient with Neuroblastoma in the setting of a germline BARD1 mutation, is there any evidence for a treatment that this patient would be particularly susceptible to?",True,True,"given disease and biomarker, return drugs",False,The US FDA has not yet approved any biomarker-based treatments for use for the treatment of patients with neuroblastoma,[],0,0,0,1,set(),set(),set(),set(),set(),"{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","
    Context information is below.
    ---------------------
    ['If a prostate cancer patient has a somatic variant in gene BARD1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a low-grade glioma patient has a somatic variant in gene BRAF (c.1799T>A or p.V600E), and is unresectable or metastatic, one recommended treatment would be Dabrafenib + Trametinib. The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of pediatric patients 1 year of age or older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. (Citation: Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s025lbl.pdf. Revised March 2023. Accessed April 6, 2023.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a pancreatic adenocarcinoma patient has a germline variant in gene BRCA1, and is metastatic, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regime. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: I have a 3 year old patient with Neuroblastoma in the setting of a germline BARD1 mutation, is there any evidence for a treatment that this patient would be particularly susceptible to?
     
    ","
    Context information is below.
    ---------------------
    ['If a prostate cancer patient has a somatic variant in gene BARD1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a low-grade glioma patient has a somatic variant in gene BRAF (c.1799T>A or p.V600E), and is unresectable or metastatic, one recommended treatment would be Dabrafenib + Trametinib. The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of pediatric patients 1 year of age or older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. (Citation: Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s025lbl.pdf. Revised March 2023. Accessed April 6, 2023.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a pancreatic adenocarcinoma patient has a germline variant in gene BRCA1, and is metastatic, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regime. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a peritoneal cancer patient has a germline variant in gene BRCA1, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: I have a 3 year old patient with Neuroblastoma in the setting of a germline BARD1 mutation, is there any evidence for a treatment that this patient would be particularly susceptible to?
     
    ","
    Context information is below.
    ---------------------
    ['If a prostate cancer patient has a somatic variant in gene BARD1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a low-grade glioma patient has a somatic variant in gene BRAF (c.1799T>A or p.V600E), and is unresectable or metastatic, one recommended treatment would be Dabrafenib + Trametinib. The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of pediatric patients 1 year of age or older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. (Citation: Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s025lbl.pdf. Revised March 2023. Accessed April 6, 2023.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a pancreatic adenocarcinoma patient has a germline variant in gene BRCA1, and is metastatic, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regime. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a peritoneal cancer patient has a germline variant in gene BRCA1, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: I have a 3 year old patient with Neuroblastoma in the setting of a germline BARD1 mutation, is there any evidence for a treatment that this patient would be particularly susceptible to?
     
    ","
    Context information is below.
    ---------------------
    ['If a prostate cancer patient has a somatic variant in gene BARD1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a low-grade glioma patient has a somatic variant in gene BRAF (c.1799T>A or p.V600E), and is unresectable or metastatic, one recommended treatment would be Dabrafenib + Trametinib. The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of pediatric patients 1 year of age or older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. (Citation: Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s025lbl.pdf. Revised March 2023. Accessed April 6, 2023.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a pancreatic adenocarcinoma patient has a germline variant in gene BRCA1, and is metastatic, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regime. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a peritoneal cancer patient has a germline variant in gene BRCA1, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: I have a 3 year old patient with Neuroblastoma in the setting of a germline BARD1 mutation, is there any evidence for a treatment that this patient would be particularly susceptible to?
     
    ","
    Context information is below.
    ---------------------
    ['If a prostate cancer patient has a somatic variant in gene BARD1, and is metastatic castration resistant prostate cancer, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a low-grade glioma patient has a somatic variant in gene BRAF (c.1799T>A or p.V600E), and is unresectable or metastatic, one recommended treatment would be Dabrafenib + Trametinib. The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of pediatric patients 1 year of age or older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. (Citation: Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s025lbl.pdf. Revised March 2023. Accessed April 6, 2023.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a pancreatic adenocarcinoma patient has a germline variant in gene BRCA1, and is metastatic, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regime. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a peritoneal cancer patient has a germline variant in gene BRCA1, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: I have a 3 year old patient with Neuroblastoma in the setting of a germline BARD1 mutation, is there any evidence for a treatment that this patient would be particularly susceptible to?
     
    "
q12,"My 20 year old patient with ALK mutated Neuroblastoma has failed therapy with broad chemotherapy, radiation, and an ALK inhibitor. What is a good next line and what evidence supports this choice?",True,True,"given disease and biomarker, return drugs",False,The US FDA has not yet approved any biomarker-based treatments for use for the treatment of patients with neuroblastoma,[],0,0,0,1,set(),set(),set(),set(),set(),"{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","
    Context information is below.
    ---------------------
    ['If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: My 20 year old patient with ALK mutated Neuroblastoma has failed therapy with broad chemotherapy, radiation, and an ALK inhibitor. What is a good next line and what evidence supports this choice?
     
    ","
    Context information is below.
    ---------------------
    ['If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: My 20 year old patient with ALK mutated Neuroblastoma has failed therapy with broad chemotherapy, radiation, and an ALK inhibitor. What is a good next line and what evidence supports this choice?
     
    ","
    Context information is below.
    ---------------------
    ['If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: My 20 year old patient with ALK mutated Neuroblastoma has failed therapy with broad chemotherapy, radiation, and an ALK inhibitor. What is a good next line and what evidence supports this choice?
     
    ","
    Context information is below.
    ---------------------
    ['If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: My 20 year old patient with ALK mutated Neuroblastoma has failed therapy with broad chemotherapy, radiation, and an ALK inhibitor. What is a good next line and what evidence supports this choice?
     
    ","
    Context information is below.
    ---------------------
    ['If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Alectinib. The U.S. Food and Drug Administration (FDA) granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. (Citation: Genentech, Inc. Alecensa (alectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf. Revised June 2018. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Lorlatinib. The U.S. Food and Drug Administration (FDA) granted approval for lorbrena for patients with ALK positive metastatic non-small cell lung cancer (NSCLC) for second- or third-line treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trial. (Citation: Pfizer, Inc. Lorbrena (lorlatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210868s001lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval for crizotinib for the treatment of patients with ALK positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a non-small cell lung cancer patient has a rearrangement in gene ALK, and is metastatic, one recommended treatment would be Ceritinib. The U.S. Food and Drug Administration (FDA) granted regular approval for ceritinib for patients with for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Zykadia (ceritinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211225s000lbl.pdf. Revised March 2019. Accessed November 12, 2020.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: My 20 year old patient with ALK mutated Neuroblastoma has failed therapy with broad chemotherapy, radiation, and an ALK inhibitor. What is a good next line and what evidence supports this choice?
     
    "
q13,"For a 17-year-old osteosarcoma patient with 50% tumor necrosis after first-line therapy and MYC amplification, are there effective salvage therapies? What evidence supports them?",True,True,"given disease and biomarker, return drugs",False,The US FDA has not yet approved any biomarker-based treatments for use for the treatment of patients with osteosarcoma,[],0,0,0,1,set(),set(),set(),set(),set(),"{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","
    Context information is below.
    ---------------------
    ['If a any solid tumor patient has a rearrangement in gene RET, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Retevmo (selpercatinib) for the treatment of adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alterantive treatment options. (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refactory (if radioactive iodine is appropriate). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a medullary thyroid cancer patient has a somatic variant in gene RET, and is advanced or metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy. (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: For a 17-year-old osteosarcoma patient with 50% tumor necrosis after first-line therapy and MYC amplification, are there effective salvage therapies? What evidence supports them?
     
    ","
    Context information is below.
    ---------------------
    ['If a any solid tumor patient has a rearrangement in gene RET, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Retevmo (selpercatinib) for the treatment of adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alterantive treatment options. (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refactory (if radioactive iodine is appropriate). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a medullary thyroid cancer patient has a somatic variant in gene RET, and is advanced or metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy. (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: For a 17-year-old osteosarcoma patient with 50% tumor necrosis after first-line therapy and MYC amplification, are there effective salvage therapies? What evidence supports them?
     
    ","
    Context information is below.
    ---------------------
    ['If a any solid tumor patient has a rearrangement in gene RET, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Retevmo (selpercatinib) for the treatment of adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alterantive treatment options. (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refactory (if radioactive iodine is appropriate). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a medullary thyroid cancer patient has a somatic variant in gene RET, and is advanced or metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy. (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: For a 17-year-old osteosarcoma patient with 50% tumor necrosis after first-line therapy and MYC amplification, are there effective salvage therapies? What evidence supports them?
     
    ","
    Context information is below.
    ---------------------
    ['If a any solid tumor patient has a rearrangement in gene RET, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Retevmo (selpercatinib) for the treatment of adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alterantive treatment options. (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refactory (if radioactive iodine is appropriate). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a medullary thyroid cancer patient has a somatic variant in gene RET, and is advanced or metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy. (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: For a 17-year-old osteosarcoma patient with 50% tumor necrosis after first-line therapy and MYC amplification, are there effective salvage therapies? What evidence supports them?
     
    ","
    Context information is below.
    ---------------------
    ['If a any solid tumor patient has a rearrangement in gene RET, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Retevmo (selpercatinib) for the treatment of adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alterantive treatment options. (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refactory (if radioactive iodine is appropriate). (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a medullary thyroid cancer patient has a somatic variant in gene RET, and is advanced or metastatic, one recommended treatment would be Selpercatinib. The U.S. Food and Drug Administration (FDA) granted approval for selpercatinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy. (Citation: Eli Lily and Company. Retevmo (selpercatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213246s008lbl.pdf. Revised September 2022. Accessed December 1, 2022.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: For a 17-year-old osteosarcoma patient with 50% tumor necrosis after first-line therapy and MYC amplification, are there effective salvage therapies? What evidence supports them?
     
    "
q14,Is there an optimal drug combination to minimize the risk of post HSCT relapse in a 2 year old with KMT2A rearranged AML?,True,True,"given disease and biomarker, return drugs; not included in the version of MOAlamanc used in the study",False,"The US FDA has not yet approved any biomarker-based treatments for use for the treatment of patients with KMT2A translocation positive AML. However, Revumenib was approved on November, 2024, which is not included in the version of MOAlamanc used in the study.",[],0,0,0,1,set(),set(),set(),set(),set(),"{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","
    Context information is below.
    ---------------------
    ['If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).', 'If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a myelodysplastic syndromes patient has a rearrangement in gene PDGFRB, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for myelodysplastic/ myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements. (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', ""If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, one recommended treatment would be Ponatinib + Chemotherapy. The U.S. Food and Drug Administration (FDA) granted accelerated approval to ponatinib in combination with chemotherapy for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Ponatinib's package insert further states that this indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete transmission (CR) at the end of induction. (Citation: Takeda Pharmaceuticals America, Inc. Iclusig (ponatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf. Revised March 2024. Accessed April 11, 2024.)."", 'If a myelodysplastic syndromes patient has a rearrangement in gene PDGFRA, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for myelodysplastic / myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements. (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, and is relapsed or refactory, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for adult patients with relapsed or refactory Philidelphia chromosome-positive acute lymphphoblastic leukemia (Ph+ ALL). (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: Is there an optimal drug combination to minimize the risk of post HSCT relapse in a 2 year old with KMT2A rearranged AML?
     
    ","
    Context information is below.
    ---------------------
    ['If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).', 'If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a myelodysplastic syndromes patient has a rearrangement in gene PDGFRB, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for myelodysplastic/ myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements. (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', ""If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, one recommended treatment would be Ponatinib + Chemotherapy. The U.S. Food and Drug Administration (FDA) granted accelerated approval to ponatinib in combination with chemotherapy for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Ponatinib's package insert further states that this indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete transmission (CR) at the end of induction. (Citation: Takeda Pharmaceuticals America, Inc. Iclusig (ponatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf. Revised March 2024. Accessed April 11, 2024.)."", 'If a myelodysplastic syndromes patient has a rearrangement in gene PDGFRA, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for myelodysplastic / myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements. (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, and is relapsed or refactory, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for adult patients with relapsed or refactory Philidelphia chromosome-positive acute lymphphoblastic leukemia (Ph+ ALL). (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: Is there an optimal drug combination to minimize the risk of post HSCT relapse in a 2 year old with KMT2A rearranged AML?
     
    ","
    Context information is below.
    ---------------------
    ['If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).', 'If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a myelodysplastic syndromes patient has a rearrangement in gene PDGFRB, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for myelodysplastic/ myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements. (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', ""If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, one recommended treatment would be Ponatinib + Chemotherapy. The U.S. Food and Drug Administration (FDA) granted accelerated approval to ponatinib in combination with chemotherapy for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Ponatinib's package insert further states that this indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete transmission (CR) at the end of induction. (Citation: Takeda Pharmaceuticals America, Inc. Iclusig (ponatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf. Revised March 2024. Accessed April 11, 2024.)."", 'If a myelodysplastic syndromes patient has a rearrangement in gene PDGFRA, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for myelodysplastic / myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements. (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, and is relapsed or refactory, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for adult patients with relapsed or refactory Philidelphia chromosome-positive acute lymphphoblastic leukemia (Ph+ ALL). (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: Is there an optimal drug combination to minimize the risk of post HSCT relapse in a 2 year old with KMT2A rearranged AML?
     
    ","
    Context information is below.
    ---------------------
    ['If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).', 'If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a myelodysplastic syndromes patient has a rearrangement in gene PDGFRB, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for myelodysplastic/ myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements. (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', ""If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, one recommended treatment would be Ponatinib + Chemotherapy. The U.S. Food and Drug Administration (FDA) granted accelerated approval to ponatinib in combination with chemotherapy for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Ponatinib's package insert further states that this indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete transmission (CR) at the end of induction. (Citation: Takeda Pharmaceuticals America, Inc. Iclusig (ponatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf. Revised March 2024. Accessed April 11, 2024.)."", 'If a myelodysplastic syndromes patient has a rearrangement in gene PDGFRA, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for myelodysplastic / myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements. (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, and is relapsed or refactory, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for adult patients with relapsed or refactory Philidelphia chromosome-positive acute lymphphoblastic leukemia (Ph+ ALL). (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: Is there an optimal drug combination to minimize the risk of post HSCT relapse in a 2 year old with KMT2A rearranged AML?
     
    ","
    Context information is below.
    ---------------------
    ['If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).', 'If a anaplastic large cell lymphoma (alcl) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of pediatric patients 1 year of age or older and young adults with relapsed or refactory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refactory systemic ALK-positive ALCL. (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a inflammatory myofibroblastic tumor (imt) patient has a rearrangement in gene ALK, one recommended treatment would be Crizotinib. The U.S. Food and Drug Administration (FDA) granted approval to crizotinib for the treatment of adult and pediatric patients 1 year of age or older with unresectable, recurrent, or refactory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT). (Citation: Pfizer, Inc. Xalkori (crizotinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202570s033lbl.pdf. Revised July 2022. Accessed August 4th, 2022.).', 'If a myelodysplastic syndromes patient has a rearrangement in gene PDGFRB, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for myelodysplastic/ myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements. (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', ""If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, one recommended treatment would be Ponatinib + Chemotherapy. The U.S. Food and Drug Administration (FDA) granted accelerated approval to ponatinib in combination with chemotherapy for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Ponatinib's package insert further states that this indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete transmission (CR) at the end of induction. (Citation: Takeda Pharmaceuticals America, Inc. Iclusig (ponatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf. Revised March 2024. Accessed April 11, 2024.)."", 'If a myelodysplastic syndromes patient has a rearrangement in gene PDGFRA, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for myelodysplastic / myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements. (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.394C>T or p.R132C), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, and is relapsed or refactory, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for adult patients with relapsed or refactory Philidelphia chromosome-positive acute lymphphoblastic leukemia (Ph+ ALL). (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', 'If a acute myeloid leukemia patient has a somatic variant in gene IDH1 (c.395G>A or p.R132H), and is newly diagnosed aml who are 75 years or older, or who have comorbities that preclude use of intensive induction chemotherapy., one recommended treatment would be Ivosidenib + Azacitidine. The U.S. Food and Drug Administration (FDA) granted approval to ivosidenib in combination with azacitidine or as a monotherapy indicated for patients with a susceptible iDH1 mutation as detected by an FDA-approved test for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. (Citation: Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211192s011lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: Is there an optimal drug combination to minimize the risk of post HSCT relapse in a 2 year old with KMT2A rearranged AML?
     
    "
q15,"For a 4 year old patient with medulloblastoma, SHH subtype, and a germline PTCH1 mutation, are there therapies specifically targeting this pathway?",True,True,"given disease and biomarker, return drugs",False,"The US FDA has not yet approved any biomarker-based treatments for use for the treatment of patients with medulloblastoma, does not have access to clinical trial information.",[],0,0,0,1,set(),set(),set(),set(),set(),"{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","
    Context information is below.
    ---------------------
    ['If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Pralsetinib. The U.S. Food and Drug Administration granted accelerated approval to pralsetinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy or who are radioactive iodine-refractory (if radioactive iodine is appropriate). (Citation: Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a colorectal cancer patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: For a 4 year old patient with medulloblastoma, SHH subtype, and a germline PTCH1 mutation, are there therapies specifically targeting this pathway?
     
    ","
    Context information is below.
    ---------------------
    ['If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Pralsetinib. The U.S. Food and Drug Administration granted accelerated approval to pralsetinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy or who are radioactive iodine-refractory (if radioactive iodine is appropriate). (Citation: Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a colorectal cancer patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: For a 4 year old patient with medulloblastoma, SHH subtype, and a germline PTCH1 mutation, are there therapies specifically targeting this pathway?
     
    ","
    Context information is below.
    ---------------------
    ['If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Pralsetinib. The U.S. Food and Drug Administration granted accelerated approval to pralsetinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy or who are radioactive iodine-refractory (if radioactive iodine is appropriate). (Citation: Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a colorectal cancer patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: For a 4 year old patient with medulloblastoma, SHH subtype, and a germline PTCH1 mutation, are there therapies specifically targeting this pathway?
     
    ","
    Context information is below.
    ---------------------
    ['If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Pralsetinib. The U.S. Food and Drug Administration granted accelerated approval to pralsetinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy or who are radioactive iodine-refractory (if radioactive iodine is appropriate). (Citation: Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a colorectal cancer patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: For a 4 year old patient with medulloblastoma, SHH subtype, and a germline PTCH1 mutation, are there therapies specifically targeting this pathway?
     
    ","
    Context information is below.
    ---------------------
    ['If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).', 'If a thyroid cancer patient has a rearrangement in gene RET, and is advanced or metastatic, one recommended treatment would be Pralsetinib. The U.S. Food and Drug Administration granted accelerated approval to pralsetinib for adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy or who are radioactive iodine-refractory (if radioactive iodine is appropriate). (Citation: Blueprint Medicines Corporation. Gavreto (pralsetinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213721s009lbl.pdf. Revised August 2023. Accessed September 6, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a colorectal cancer patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: For a 4 year old patient with medulloblastoma, SHH subtype, and a germline PTCH1 mutation, are there therapies specifically targeting this pathway?
     
    "
q16,"For toddler with unresectable hepatoblastoma and a CTNNB1 mutation, are there targeted therapies that target the impacted pathway that would best decrease the likeliohood of liver transplant?",True,True,"given disease and biomarker, return drugs",False,"The US FDA has not yet approved any biomarker-based treatments for use for the treatment of patients with hepatoblastoma. However, there is clinical evidence that CTNNB1 is associated with favorable prognosis in patients with medulloblastoma.",[],0,0,0,1,set(),set(),set(),set(),set(),"{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","
    Context information is below.
    ---------------------
    ['If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a intrahepatic cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is locally advanced or metastatic, one recommended treatment would be Futibatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lytgobi (futibatinib) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 rearrangements. (Citation: Taiho Pharmaceutical Co., Ltd. Lytgobi (futibatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf. Revised September 2022. Accessed October 6th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: For toddler with unresectable hepatoblastoma and a CTNNB1 mutation, are there targeted therapies that target the impacted pathway that would best decrease the likeliohood of liver transplant?
     
    ","
    Context information is below.
    ---------------------
    ['If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a intrahepatic cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is locally advanced or metastatic, one recommended treatment would be Futibatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lytgobi (futibatinib) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 rearrangements. (Citation: Taiho Pharmaceutical Co., Ltd. Lytgobi (futibatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf. Revised September 2022. Accessed October 6th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: For toddler with unresectable hepatoblastoma and a CTNNB1 mutation, are there targeted therapies that target the impacted pathway that would best decrease the likeliohood of liver transplant?
     
    ","
    Context information is below.
    ---------------------
    ['If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a intrahepatic cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is locally advanced or metastatic, one recommended treatment would be Futibatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lytgobi (futibatinib) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 rearrangements. (Citation: Taiho Pharmaceutical Co., Ltd. Lytgobi (futibatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf. Revised September 2022. Accessed October 6th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: For toddler with unresectable hepatoblastoma and a CTNNB1 mutation, are there targeted therapies that target the impacted pathway that would best decrease the likeliohood of liver transplant?
     
    ","
    Context information is below.
    ---------------------
    ['If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a intrahepatic cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is locally advanced or metastatic, one recommended treatment would be Futibatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lytgobi (futibatinib) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 rearrangements. (Citation: Taiho Pharmaceutical Co., Ltd. Lytgobi (futibatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf. Revised September 2022. Accessed October 6th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: For toddler with unresectable hepatoblastoma and a CTNNB1 mutation, are there targeted therapies that target the impacted pathway that would best decrease the likeliohood of liver transplant?
     
    ","
    Context information is below.
    ---------------------
    ['If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a any solid tumor patient has high mutational burden, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Larotrectinib. The U.S. Food and Drug Administration (FDA) granted approval for larotrectinib for the treatment of adult and pediatric with solid tumors that have NTRK gene fusions without a known resistance mechanism, are metastatic or surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or have progressed following treatment. Continued approval for this indication may be contingent upon veritifcation and description of clinical benefit in a confirmatory trials. (Citation: Loxo Oncology, Inc. Vitrakvi (larotrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210861s000lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a intrahepatic cholangiocarcinoma patient has a rearrangement in gene FGFR2, and is locally advanced or metastatic, one recommended treatment would be Futibatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Lytgobi (futibatinib) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 rearrangements. (Citation: Taiho Pharmaceutical Co., Ltd. Lytgobi (futibatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801s000lbl.pdf. Revised September 2022. Accessed October 6th, 2022.).', 'If a any solid tumor patient has a rearrangement in gene NTRK1, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK2, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient has a rearrangement in gene NTRK3, one recommended treatment would be Entrectinib. The U.S. Food and Drug Administration (FDA) granted accelerated approval for entrectinib for adult and pediatric patients older than 1 month with solid tumors that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy. (Citation: Genentech, Inc. Rozlytrek (entrectinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/212725Orig1s009lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a any solid tumor patient is MSI-high, and is unresectable or metastatic, one recommended treatment would be Pembrolizumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: For toddler with unresectable hepatoblastoma and a CTNNB1 mutation, are there targeted therapies that target the impacted pathway that would best decrease the likeliohood of liver transplant?
     
    "
q17,"I have a patient with de novo metastatic HR+ breast cancer with both a somatic AKT mutation and a germline BRCA2 mutation - what are the standard, recommended first- and second-line treatments for this patient?",True,True,"given disease and biomarker, return drugs; HER2-related",True,"Two therapeutic hypotheses to consider for this patient are either PARP or PI3K/Akt/mTOR inhibition, though all treatment options are indicated for patients that have HER2-negative breast cancer. For first line treatment, talazoparib is approved for use and indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer. For second line treatments, options will vary depending on the type of first line treatment. Capivasertib in combination with fulvestrant is approved for use for the treatment of adult patients with locally advanced or metastatic HR-positive, HER2-negative breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. Olaparib is also approved for use for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative (i) metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting; and (ii) high risk early breast cancer who have been treated with chemotherapy in the neoadjuvant or adjuvant setting.","[{'talazoparib'}, {'capivasertib', 'fulvestrant'}, {'olaparib'}]",0,3,0,1,set(),set(),set(),set(),set(),"{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","
    Context information is below.
    ---------------------
    ['If a peritoneal cancer patient has a somatic variant in gene BRCA2, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a peritoneal cancer patient has a germline variant in gene BRCA2, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative locally advanced or metastatic, one recommended treatment would be Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.).', 'If a pancreatic adenocarcinoma patient has a germline variant in gene BRCA2, and is metastatic, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regime. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a peritoneal cancer patient has a somatic variant in gene BRCA1, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for approved olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a epithelial ovarian cancer patient has a somatic variant in gene BRCA2, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a epithelial ovarian cancer patient has a somatic variant in gene BRCA2, and is advanced, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA1, and is her2-negative locally advanced or metastatic, one recommended treatment would be Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: I have a patient with de novo metastatic HR+ breast cancer with both a somatic AKT mutation and a germline BRCA2 mutation - what are the standard, recommended first- and second-line treatments for this patient?
     
    ","
    Context information is below.
    ---------------------
    ['If a peritoneal cancer patient has a somatic variant in gene BRCA2, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a peritoneal cancer patient has a germline variant in gene BRCA2, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative locally advanced or metastatic, one recommended treatment would be Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.).', 'If a pancreatic adenocarcinoma patient has a germline variant in gene BRCA2, and is metastatic, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regime. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a peritoneal cancer patient has a somatic variant in gene BRCA1, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for approved olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a epithelial ovarian cancer patient has a somatic variant in gene BRCA2, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a epithelial ovarian cancer patient has a somatic variant in gene BRCA2, and is advanced, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA1, and is her2-negative locally advanced or metastatic, one recommended treatment would be Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: I have a patient with de novo metastatic HR+ breast cancer with both a somatic AKT mutation and a germline BRCA2 mutation - what are the standard, recommended first- and second-line treatments for this patient?
     
    ","
    Context information is below.
    ---------------------
    ['If a peritoneal cancer patient has a somatic variant in gene BRCA2, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a peritoneal cancer patient has a germline variant in gene BRCA2, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative locally advanced or metastatic, one recommended treatment would be Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.).', 'If a pancreatic adenocarcinoma patient has a germline variant in gene BRCA2, and is metastatic, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regime. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a peritoneal cancer patient has a somatic variant in gene BRCA1, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for approved olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a epithelial ovarian cancer patient has a somatic variant in gene BRCA2, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a epithelial ovarian cancer patient has a somatic variant in gene BRCA2, and is advanced, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA1, and is her2-negative locally advanced or metastatic, one recommended treatment would be Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: I have a patient with de novo metastatic HR+ breast cancer with both a somatic AKT mutation and a germline BRCA2 mutation - what are the standard, recommended first- and second-line treatments for this patient?
     
    ","
    Context information is below.
    ---------------------
    ['If a peritoneal cancer patient has a somatic variant in gene BRCA2, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a peritoneal cancer patient has a germline variant in gene BRCA2, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative locally advanced or metastatic, one recommended treatment would be Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.).', 'If a pancreatic adenocarcinoma patient has a germline variant in gene BRCA2, and is metastatic, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regime. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a peritoneal cancer patient has a somatic variant in gene BRCA1, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for approved olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a epithelial ovarian cancer patient has a somatic variant in gene BRCA2, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a epithelial ovarian cancer patient has a somatic variant in gene BRCA2, and is advanced, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA1, and is her2-negative locally advanced or metastatic, one recommended treatment would be Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: I have a patient with de novo metastatic HR+ breast cancer with both a somatic AKT mutation and a germline BRCA2 mutation - what are the standard, recommended first- and second-line treatments for this patient?
     
    ","
    Context information is below.
    ---------------------
    ['If a peritoneal cancer patient has a somatic variant in gene BRCA2, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a peritoneal cancer patient has a germline variant in gene BRCA2, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative locally advanced or metastatic, one recommended treatment would be Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.).', 'If a pancreatic adenocarcinoma patient has a germline variant in gene BRCA2, and is metastatic, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regime. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a peritoneal cancer patient has a somatic variant in gene BRCA1, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for approved olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a epithelial ovarian cancer patient has a somatic variant in gene BRCA2, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a epithelial ovarian cancer patient has a somatic variant in gene BRCA2, and is advanced, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA1, and is her2-negative locally advanced or metastatic, one recommended treatment would be Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: I have a patient with de novo metastatic HR+ breast cancer with both a somatic AKT mutation and a germline BRCA2 mutation - what are the standard, recommended first- and second-line treatments for this patient?
     
    "
q18,I have a patient with an initial diagnosis of cT3N1 HER2+ breast cancer who received neoadjuvant TCHP and had 1cm of residual disease at surgery. What is the recommended adjuvant treatment for this patient and what are the clinical trials that I should consider?,True,True,"given disease and biomarker, return drugs; HER2-related",True,"While this version of MOAlmanac does not directly curate HER2+ status as a biomarker, a number of FDA approvals and companion diagnostics include ERBB2 amplifications for approvals based on HER2+. For FDA approvals for patients with breast cancer: Ado-Trastuzumab Emtansine; Capecitabine + Trastuzumab + Tucatinib; Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab; Lapatinib; Margetuximab-cmkb + Chemotherapy; Neratinib; Neratinib + Capecitabine; Pertuzumab + Trastuzumab; Trastuzumab; Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab","[{'ado-trastuzumab emtansine'}, {'trastuzumab', 'tucatinib', 'capecitabine'}, {'trastuzumab', 'hyaluronidase-zzxf', 'pertuzumab', 'chemotherapy'}, {'lapatinib'}, {'chemotherapy', 'margetuximab-cmkb'}, {'neratinib'}, {'capecitabine', 'neratinib'}, {'trastuzumab', 'pertuzumab'}, {'trastuzumab'}, {'trastuzumab', 'pertuzumab', 'hyaluronidase-zzxf', 'docetaxel'}, {'trastuzumab', 'pertuzumab', 'docetaxel'}]",2,9,0,0,"{frozenset({'pertuzumab', 'trastuzumab'}), frozenset({'chemotherapy', 'pertuzumab', 'hyaluronidase-zzxf', 'trastuzumab'})}","{frozenset({'pertuzumab', 'trastuzumab'}), frozenset({'chemotherapy', 'pertuzumab', 'hyaluronidase-zzxf', 'trastuzumab'})}","{frozenset({'pertuzumab', 'trastuzumab'})}","{frozenset({'pertuzumab', 'trastuzumab'}), frozenset({'chemotherapy', 'pertuzumab', 'hyaluronidase-zzxf', 'trastuzumab'})}","{frozenset({'pertuzumab', 'trastuzumab'})}","{
    ""Status"": ""success"",
    ""Treatment 1"": {
        ""Disease Name"": ""HER2-positive breast cancer"",
        ""Disease Phase or Condition"": ""Adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence"",
        ""Drug Name"": ""Pertuzumab + Trastuzumab"",
        ""Prior Treatment or Resistance Status"": ""Patients with HER2-positive early breast cancer at high risk of recurrence"",
        ""Genomic Features"": ""HER2-positive"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf""
    },
    ""Treatment 2"": {
        ""Disease Name"": ""HER2-positive breast cancer"",
        ""Disease Phase or Condition"": ""Adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence"",
        ""Drug Name"": ""Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab"",
        ""Prior Treatment or Resistance Status"": ""Patients with HER2-positive early breast cancer at high risk of recurrence"",
        ""Genomic Features"": ""HER2-positive"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf""
    }
}","{
    ""Status"": ""success"",
    ""Treatment 1"": {
        ""Disease Name"": ""HER2-positive breast cancer"",
        ""Disease Phase or Condition"": ""Adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence"",
        ""Drug Name"": ""Pertuzumab + Trastuzumab"",
        ""Prior Treatment or Resistance Status"": ""Patients with HER2-positive early breast cancer at high risk of recurrence"",
        ""Genomic Features"": ""HER2-positive"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf""
    },
    ""Treatment 2"": {
        ""Disease Name"": ""HER2-positive breast cancer"",
        ""Disease Phase or Condition"": ""Adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence"",
        ""Drug Name"": ""Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab"",
        ""Prior Treatment or Resistance Status"": ""Patients with HER2-positive early breast cancer at high risk of recurrence"",
        ""Genomic Features"": ""HER2-positive"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf""
    }
}","{
    ""Status"": ""success"",
    ""Treatment 1"": {
        ""Disease Name"": ""HER2-positive breast cancer"",
        ""Disease Phase or Condition"": ""Adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence"",
        ""Drug Name"": ""Pertuzumab + Trastuzumab"",
        ""Prior Treatment or Resistance Status"": ""Patients with HER2-positive early breast cancer at high risk of recurrence"",
        ""Genomic Features"": ""HER2-positive"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf""
    }
}","{
    ""Status"": ""success"",
    ""Treatment 1"": {
        ""Disease Name"": ""HER2-positive breast cancer"",
        ""Disease Phase or Condition"": ""Adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence"",
        ""Drug Name"": ""Pertuzumab + Trastuzumab"",
        ""Prior Treatment or Resistance Status"": ""Patients with HER2-positive early breast cancer at high risk of recurrence"",
        ""Genomic Features"": ""HER2-positive"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf""
    },
    ""Treatment 2"": {
        ""Disease Name"": ""HER2-positive breast cancer"",
        ""Disease Phase or Condition"": ""Adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence"",
        ""Drug Name"": ""Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab"",
        ""Prior Treatment or Resistance Status"": ""Patients with HER2-positive early breast cancer at high risk of recurrence"",
        ""Genomic Features"": ""HER2-positive"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf""
    }
}","{
    ""Status"": ""success"",
    ""Treatment 1"": {
        ""Disease Name"": ""HER2-positive breast cancer"",
        ""Disease Phase or Condition"": ""Adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence"",
        ""Drug Name"": ""Pertuzumab + Trastuzumab"",
        ""Prior Treatment or Resistance Status"": ""Patients with HER2-positive early breast cancer at high risk of recurrence"",
        ""Genomic Features"": ""HER2-positive"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf""
    }
}","
    Context information is below.
    ---------------------
    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is locally advanced, inflammatory, or early stage, one recommended treatment would be Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with chemotherapy for the following indications: neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Lapatinib + Trastuzumab. Lapatinib is a kinase inhibitor indicated in combination with: (1) capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Limitations of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib in combination with capecitabine. (2) letrozole for the treatment of postmenopausal women with hormone receptorpositive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. (Citation: Novartis Pharmaceuticals Corporation. Tykerb (lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s024lbl.pdf. Revised December 2018. Accessed November 12, 2020.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: I have a patient with an initial diagnosis of cT3N1 HER2+ breast cancer who received neoadjuvant TCHP and had 1cm of residual disease at surgery. What is the recommended adjuvant treatment for this patient and what are the clinical trials that I should consider?
     
    ","
    Context information is below.
    ---------------------
    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is locally advanced, inflammatory, or early stage, one recommended treatment would be Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with chemotherapy for the following indications: neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Lapatinib + Trastuzumab. Lapatinib is a kinase inhibitor indicated in combination with: (1) capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Limitations of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib in combination with capecitabine. (2) letrozole for the treatment of postmenopausal women with hormone receptorpositive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. (Citation: Novartis Pharmaceuticals Corporation. Tykerb (lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s024lbl.pdf. Revised December 2018. Accessed November 12, 2020.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: I have a patient with an initial diagnosis of cT3N1 HER2+ breast cancer who received neoadjuvant TCHP and had 1cm of residual disease at surgery. What is the recommended adjuvant treatment for this patient and what are the clinical trials that I should consider?
     
    ","
    Context information is below.
    ---------------------
    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is locally advanced, inflammatory, or early stage, one recommended treatment would be Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with chemotherapy for the following indications: neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Lapatinib + Trastuzumab. Lapatinib is a kinase inhibitor indicated in combination with: (1) capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Limitations of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib in combination with capecitabine. (2) letrozole for the treatment of postmenopausal women with hormone receptorpositive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. (Citation: Novartis Pharmaceuticals Corporation. Tykerb (lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s024lbl.pdf. Revised December 2018. Accessed November 12, 2020.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: I have a patient with an initial diagnosis of cT3N1 HER2+ breast cancer who received neoadjuvant TCHP and had 1cm of residual disease at surgery. What is the recommended adjuvant treatment for this patient and what are the clinical trials that I should consider?
     
    ","
    Context information is below.
    ---------------------
    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is locally advanced, inflammatory, or early stage, one recommended treatment would be Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with chemotherapy for the following indications: neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Lapatinib + Trastuzumab. Lapatinib is a kinase inhibitor indicated in combination with: (1) capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Limitations of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib in combination with capecitabine. (2) letrozole for the treatment of postmenopausal women with hormone receptorpositive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. (Citation: Novartis Pharmaceuticals Corporation. Tykerb (lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s024lbl.pdf. Revised December 2018. Accessed November 12, 2020.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: I have a patient with an initial diagnosis of cT3N1 HER2+ breast cancer who received neoadjuvant TCHP and had 1cm of residual disease at surgery. What is the recommended adjuvant treatment for this patient and what are the clinical trials that I should consider?
     
    ","
    Context information is below.
    ---------------------
    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is locally advanced, inflammatory, or early stage, one recommended treatment would be Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with chemotherapy for the following indications: neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Lapatinib + Trastuzumab. Lapatinib is a kinase inhibitor indicated in combination with: (1) capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Limitations of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib in combination with capecitabine. (2) letrozole for the treatment of postmenopausal women with hormone receptorpositive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. (Citation: Novartis Pharmaceuticals Corporation. Tykerb (lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s024lbl.pdf. Revised December 2018. Accessed November 12, 2020.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: I have a patient with an initial diagnosis of cT3N1 HER2+ breast cancer who received neoadjuvant TCHP and had 1cm of residual disease at surgery. What is the recommended adjuvant treatment for this patient and what are the clinical trials that I should consider?
     
    "
q19,"I have a patient with metastatic HR-negative, HER2-low, PD-L1-negative, breast cancer with no germline BRCA mutation.  For second line, is T-DXd or Sacituzumab govitecan preferred?",True,True,"given disease and biomarker, return drugs; not included in the version of MOAlamanc used in the study",True,"Either T-DXd or SG could be used; we generally use SG at this point given a large phase III trial (ASCENT) with PFS and OS benefit. Destiny-BREAST04 had a smaller cohort of TNBC. Both T-DXd and SG are FDA approved for MBC after 1+ prior lines of chemotherapy; SG is approved for HER2 null, while T-DXd is approved for HER2-low or -ultralow. T-DXd is associated with higher rates of interstitial lung disease, and cardiac function must be monitored given anti-HER2 activity. SG has more dense alopecia and higher rates of neutropenia.","[{'sacituzumab govitecan'}, {'trastuzumab deruxtecan'}]",0,2,0,1,set(),set(),set(),set(),set(),"{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","{
    ""Status"": ""no_match"",
    ""Message"": ""No drugs are FDA-approved for the provided context""
}","
    Context information is below.
    ---------------------
    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with docetaxel for treatment of patients with HER-2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: I have a patient with metastatic HR-negative, HER2-low, PD-L1-negative, breast cancer with no germline BRCA mutation.  For second line, is T-DXd or Sacituzumab govitecan preferred?
     
    ","
    Context information is below.
    ---------------------
    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with docetaxel for treatment of patients with HER-2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: I have a patient with metastatic HR-negative, HER2-low, PD-L1-negative, breast cancer with no germline BRCA mutation.  For second line, is T-DXd or Sacituzumab govitecan preferred?
     
    ","
    Context information is below.
    ---------------------
    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with docetaxel for treatment of patients with HER-2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: I have a patient with metastatic HR-negative, HER2-low, PD-L1-negative, breast cancer with no germline BRCA mutation.  For second line, is T-DXd or Sacituzumab govitecan preferred?
     
    ","
    Context information is below.
    ---------------------
    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with docetaxel for treatment of patients with HER-2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: I have a patient with metastatic HR-negative, HER2-low, PD-L1-negative, breast cancer with no germline BRCA mutation.  For second line, is T-DXd or Sacituzumab govitecan preferred?
     
    ","
    Context information is below.
    ---------------------
    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with docetaxel for treatment of patients with HER-2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: I have a patient with metastatic HR-negative, HER2-low, PD-L1-negative, breast cancer with no germline BRCA mutation.  For second line, is T-DXd or Sacituzumab govitecan preferred?
     
    "
q20,"If a bladder cancer patient has FGFR3 mutations, what would be the recommended next lines of treatment?",True,True,"given disease and biomarker, return drugs",True,"The US FDA has approved Erdafitnib for use for the treatment of patients with locally advanced or metastatic  urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy.",[{'erdafitinib'}],1,0,0,0,{frozenset({'erdafitinib'})},{frozenset({'erdafitinib'})},{frozenset({'erdafitinib'})},{frozenset({'erdafitinib'})},{frozenset({'erdafitinib'})},"{
    ""Status"": ""success"",
    ""Treatment 1"": {
        ""Disease Name"": ""Urothelial carcinoma"",
        ""Disease Phase or Condition"": ""Locally advanced or metastatic"",
        ""Drug Name"": ""Erdafitinib"",
        ""Prior Treatment or Resistance Status"": ""Progressed during or following at least one line of systemic therapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy"",
        ""Genomic Features"": ""FGFR3 genetic alterations (e.g., c.742C>T or p.R248C, c.746C>G or p.S249C, c.1118A>G or p.Y373C, c.1180G>T or p.G370C)"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf""
    }
}","{
    ""Status"": ""success"",
    ""Treatment 1"": {
        ""Disease Name"": ""Urothelial carcinoma (Bladder cancer)"",
        ""Disease Phase or Condition"": ""Locally advanced or metastatic"",
        ""Drug Name"": ""Erdafitinib"",
        ""Prior Treatment or Resistance Status"": ""Progressed during or following at least one line of systemic therapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy"",
        ""Genomic Features"": ""FGFR3 mutations (c.742C>T or p.R248C, c.746C>G or p.S249C, c.1118A>G or p.Y373C, c.1180G>T or p.G370C)"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf""
    }
}","{
    ""Status"": ""success"",
    ""Treatment 1"": {
        ""Disease Name"": ""Urothelial carcinoma (Bladder cancer)"",
        ""Disease Phase or Condition"": ""Locally advanced or metastatic"",
        ""Drug Name"": ""Erdafitinib"",
        ""Prior Treatment or Resistance Status"": ""Progressed during or following at least one line of systemic therapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy"",
        ""Genomic Features"": ""FGFR3 mutations (c.742C>T or p.R248C, c.746C>G or p.S249C, c.1118A>G or p.Y373C, c.1180G>T or p.G370C)"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf""
    }
}","{
    ""Status"": ""success"",
    ""Treatment 1"": {
        ""Disease Name"": ""Urothelial carcinoma"",
        ""Disease Phase or Condition"": ""Locally advanced or metastatic"",
        ""Drug Name"": ""Erdafitinib"",
        ""Prior Treatment or Resistance Status"": ""Progressed during or following at least one line of systemic therapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy"",
        ""Genomic Features"": ""FGFR3 mutations (c.742C>T or p.R248C, c.746C>G or p.S249C, c.1118A>G or p.Y373C, c.1180G>T or p.G370C)"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf""
    }
}","{
    ""Status"": ""success"",
    ""Treatment 1"": {
        ""Disease Name"": ""Urothelial carcinoma (Bladder cancer)"",
        ""Disease Phase or Condition"": ""Locally advanced or metastatic"",
        ""Drug Name"": ""Erdafitinib"",
        ""Prior Treatment or Resistance Status"": ""Progressed during or following at least one line of systemic therapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy"",
        ""Genomic Features"": ""FGFR3 mutations (c.742C>T or p.R248C, c.746C>G or p.S249C, c.1118A>G or p.Y373C, c.1180G>T or p.G370C)"",
        ""FDA-approval status"": ""Approved"",
        ""Link to FDA-approved Label"": ""https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf""
    }
}","
    Context information is below.
    ---------------------
    ['If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (nonsense), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR, one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: If a bladder cancer patient has FGFR3 mutations, what would be the recommended next lines of treatment?
     
    ","
    Context information is below.
    ---------------------
    ['If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (nonsense), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR, one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: If a bladder cancer patient has FGFR3 mutations, what would be the recommended next lines of treatment?
     
    ","
    Context information is below.
    ---------------------
    ['If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (nonsense), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR, one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: If a bladder cancer patient has FGFR3 mutations, what would be the recommended next lines of treatment?
     
    ","
    Context information is below.
    ---------------------
    ['If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (nonsense), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR, one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: If a bladder cancer patient has FGFR3 mutations, what would be the recommended next lines of treatment?
     
    ","
    Context information is below.
    ---------------------
    ['If a urothelial carcinoma patient has a rearrangement in gene FGFR3, and is locally advanced or metastatic., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.742C>T or p.R248C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.746C>G or p.S249C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1118A>G or p.Y373C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a urothelial carcinoma patient has a somatic variant in gene FGFR3 (c.1180G>T or p.G370C), and is locally advanced or metastatic, progressed during or following at least one line of prior platinum containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum containing chemotherapy., one recommended treatment would be Erdafitinib. The U.S. Food and Drug Administration (FDA) has granted approval to erdafitinib for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, and has progressed during or following at least one line of systemic therapy, as determined by an FDA-approved companion diagnostic. Erdafitinib is not recommended for the treatment of patients who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy. (Citation: Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212018s007s008s009lbl.pdf. Revised January 2024. Accessed January 25, 2024.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (nonsense), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR, one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).', 'If a cholangiocarcinoma patient has a rearrangement in gene FGFR2, one recommended treatment would be Pemigatinib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval to Pemazyre (pemigatinib). Pemigatinib is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement as detected by an FDA-approved test. (Citation: Incyte Corporation. Pemazyre (pemigatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2022/213736s002lbl.pdf. Revised August 2022. Accessed September 8th, 2022.).']
    ---------------------
    
    If no matching FDA-approved drugs are found, please return message with the following JSON schema:
    {
        ""Status"": ""no_match"",
        ""Message"": ""No drugs are FDA-approved for the provided context""
    }
    
    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:
    {
        ""Status"": ""success"",
        ""Treatment 1"": {
            ""Disease Name"": ,
            ""Disease Phase or Condition"": ,
            ""Drug Name"": ,
            ""Prior Treatment or Resistance Status"": ,
            ""Genomic Features"": 
            ""FDA-approval status"":
            ""Link to FDA-approved Label"":
            }
    }
    Query: If a bladder cancer patient has FGFR3 mutations, what would be the recommended next lines of treatment?
     
    "
